Published in final edited form as:

Cell Mol Life Sci. 2008 May ; 65(9): 1311–1334. doi:10.1007/s00018-008-7462-2.

Substrate Specificity of γ -Secretase and Other Intramembrane Proteases

Andrew J. Beel and Charles R. Sanders

Dept. of Biochemistry and Center for Structural Biology Vanderbilt University School of Medicine, Nashville, TN, USA

Abstract

γ -Secretase is a promiscuous protease that cleaves bitopic membrane proteins within the lipid bilayer. Elucidating both the mechanistic basis of γ -secretase proteolysis and the precise factors regulating substrate identification is important because modulation of this biochemical degradative process can have important consequences in a physiological and pathophysiological context. Herein, we briefly review such information for all major classes of intramembranously-cleaving proteases (I-CLiPs), with an emphasis on γ -secretase, an I-CLiP closely linked to the etiology of Alzheimer's disease. A large body of emerging data allows us to survey the substrates of γ -secretase to ascertain the conformational features that predispose a peptide to cleavage by this enigmatic protease. Because substrate specificity *in vivo* is closely linked to the relative subcellular compartmentalization of γ -secretase and its substrates, we also survey the voluminous body of literature concerning the traffic of γ -secretase and its most prominent substrate, the amyloid precursor protein (APP).

Keywords

intramembrane; proteases; proteolysis; secretase; rhomboid; substrates; S2P; amyloid precursor protein; I-CLiPs; Alzheimer's disease; lipid rafts; presenilin

Introduction

Until recently a little known phenomenon, regulated intramembrane proteolysis (RIP) has emerged as a major pathway of signal transduction and cellular homeostasis [1,2]. The remarkable feat of catalyzing a hydrolytic reaction within the hydrophobic interior of a lipid bilayer is carried out by class of proteins known as I-CLiPs (intramembranously-cleaving proteases). A variety of I-CLiPs have been discovered and are classified into three groups as outlined below [1]. Key properties of these unique enzymes are summarized in Figure 1.

Intramembranously-Cleaving Metalloproteases: Site 2 Protease Family

Site 2 Protease (S2P) is the founding member of the metalloprotease subfamily of I-CLiPs [3], and cleaves both the sterol-regulatory element-binding proteins (SREBPs) and activating transcription factor 6 (ATF6) [2] in the Golgi membrane [4]. SREBP, the prototypical substrate of S2P, has two TM domains connected by a short luminal loop with two large cytosolic N- and C-terminal domains [5]. SREBP is initially cleaved in its luminal domain by site 1 protease (S1P) and subsequently by an S2P-mediated intramembraneous cleavage, the latter of which

releases the cytosolic N-terminal bHLH-Zip domain. This domain translocates to the nucleus and elevates transcription of genes involved in cholesterol biosynthesis [6]. Its liberation is strongly dependent on endogenous sterol levels [7] via sterol-induced control of the subcellular localization of SREBP [8] (Figure 2). The involvement of an escort protein, the SREBP cleavage-activating protein (SCAP), was detected during studies of cells that were resistant to modulation of proteolysis by sterol levels [9]. The modulatory properties of sterols derive from their ability to cause SCAP — and in turn SREBP (via an interaction between its C-terminus and that of SCAP [10]) — to bind to ER-resident anchor proteins known as Insigs [11,12]. In a similar manner, oxysterols bind to Insigs, thereby causing Insigs to bind to SCAP [13]. In either case, the anchoring of SREBP to Insigs prevents the translocation of SREBP from the endoplasmic reticulum to the Golgi, wherein its proteolysis occurs. High sterol levels therefore regulate a negative feedback system: by inhibiting SREBP processing, the transcription of genes implicated in cholesterol biosynthesis remains at low levels. Sterol depletion abrogates the Insig-SCAP interaction, allowing the SREBP-SCAP complex to enter (COP)II-coated vesicles for anterograde transport to the Golgi [14], wherein SREBP is proteolyzed by S1P [15]. S2P proteolysis, which is not regulated by sterol levels, constitutively occurs after S1P proteolysis.

The precise factors disposing substrate to S2P proteolysis have been investigated, and primary structural characteristics within the transmembrane domain appear to be dispensable for the enzyme-substrate recognition process, akin to the current paradigm for substrate recognition by γ -secretase (discussed below) and some other I-CLiPs. Biochemical studies have identified sequence elements on both sides of the membrane that are required for efficient proteolysis, namely an arginine residue in the short luminal loop and a cytosolically-located tetrapeptide sequence DRSR [16]. Substitution of the crucial arginine residue with alanine precluded proteolysis, whereas a more conservative substitution (lysine) did not have an inhibitory effect [16]. Later studies revealed that initial sterol-induced cleavage within the luminal loop by site 1 protease (S1P), a membrane-embedded serine protease, occurs in proximity to the conserved arginine residue [5,17]. Following S1P proteolysis, S2P cleaves SREBP substrates intramembranously between a leucine and cysteine [18], which is located three residues to the C-terminal side of the critical DRSR motif. However, neither the leucine nor cysteine was found to be necessary for cleavage, nor were many of the conserved residues within the transmembrane domain as shown by singly replacing each TM residue with alanine [18]. These data suggest that strict conservation of the sequences proximal to the cleavage site and within the TMD is unnecessary for S2P activity. However, at least one member of the universally-conserved asparagine-proline (NP) pair is required. This dipeptide, which is located in the middle of the first SREBP TMD, has been proposed to facilitate unwinding of the transmembrane α -helix, thereby potentiating exposure of backbone residues in the protease active site [19].

Five features observed for the cleavage of SREBP — the requirement for interruption of the transmembrane helix, the dispensability of primary structure immediately proximal to the cleavage site, a preliminary ectodomain cleavage as a prerequisite for intramembranous proteolysis, the involvement of escort proteins, and the release of biologically-active factors — are not unique to S2P but reflect features for other enzymes of the I-CLiP family.

Intramembranously-Cleaving Serine Proteases: Rhomboid Family

In *Drosophila* the founding member of the rhomboid serine protease family — Rhomboid-1 — is responsible for the proteolysis of Spitz [20], the liberated domain of which is involved in signaling through receptor tyrosine kinases [21]. Rhomboids are ubiquitously present in all forms of life on earth, and participate in diverse biological pathways such as quorum-sensing in *Providencia stuartii* and signaling via the epidermal growth factor (EGF) receptor in

Drosophila. Rhomboid is also implicated in a number of human diseases, such as type II diabetes and autosomal-dominant optical atrophy [20]. Rhomboids were initially believed to employ a catalytic triad (Asx, His, Ser) akin to classical serine proteases such as trypsin, chymotrypsin, and elastase; however, recent studies have indicated that rhomboid's Asn residue is dispensable for catalytic activity, leading to a catalytic dyad model of proteolysis [22], which has been corroborated by crystallographic analyses of rhomboid proteases [23-25]. These studies revealed a catalytic dyad buried within the membrane, in addition to novel structural features that permit substrate selectivity and intramembrane proteolysis. GlpG, a rhomboid from *E. Coli*, possesses six transmembrane (TM) helices (TM1-6). As a consequence of helix-destabilizing glycine residues, TM4 is shorter than a typical membrane-spanning alpha helix. This results in a peninsular aqueous cavity in the membrane plane, surrounded on three sides by TM helices and solvent-exposed on the fourth to the depth at which the N-terminal end of TM4 originates [23,24]. It is within this hydrophilic cleft that scission of a transmembrane substrate is believed to occur. Ben-Shem et al. suggested that substrate helix destabilization permits contact between the enzymatic active site and the scissile bond at a crevice between TM2 and TM5 [24]. TM5 is believed to act as a dynamic gating system for substrate entry to the active site [26]. The problem of bringing water into the lipophilic context of the bilayer is resolved by the crystallographic data--the curtailed length of TM4 and the provision of polar residues by other TM helices surrounding the active site permit water accessibility within the plane of the bilayer [27]. Wang et al. propose the upper segment of the TM helix of the substrate unfolds within the active site, thereby exposing the scissile bond to hydrolysis. The crystal structures of GlpG inform on its mechanism of intramembrane proteolysis; however, the lack of an apparent evolutionary relationship between rhomboid-type proteases and other I-CLiPs precludes generalization of this mechanistic information [28].

Rhomboid proteolysis, like that of S2P, also depends on the relative subcellular localization of the various components involved in the process. Indeed, the similarities between this pathway and that of SREBP proteolysis are striking. Spitz, a prototypical substrate for Rhomboid proteases in *Drosophila*, is constitutively localized to the ER, whereas Rhomboid is found in the Golgi apparatus [21]. Cleavage of Spitz is therefore regulated by its intracellular traffic, which requires involvement of an escort protein, Star. Co-translocation of Star and Spitz from ER to Golgi allows interaction between Rhomboid and Spitz, leading to proteolytic degradation of the latter and its subsequent export from the cell [21,29].

Studies of the sequence requirements for Rhomboid substrates have demonstrated an importance for helix-destabilization, analogous to that observed for S2P substrates. Insertion of the Spitz TMD into other proteins that are normally not cleaved by Rhomboid proteases led to the degradation of the chimeric constructs, suggesting that the essential features for proteolysis are contained within the TMD of Rhomboid substrates. Later analyses revealed that a conserved motif in the Spitz TMD with low helical propensity provided the basis for Rhomboid substrate specificity [30]. Thus, substrate conformation and/or dynamics determine its susceptibility to rhomboid cleavage, as was observed for S2P. Urban and Freeman found that the luminal portion of the TMD was most critical for Rhomboid proteolysis. Two consecutive residues (GA) contained therein, when inserted into non-substrates, allowed these peptides to be processed efficiently. Insertion of β -branched amino acids, which decrease local helical propensity, also enhanced proteolysis [30]. Another recent study confirmed the importance of helix-destabilizing residues; however, no consensus sequence was identified, and different members of the Rhomboid family were shown to exhibit distinct substrate preferences [31], suggesting that substrate recognition involves other structural elements distal from the cleavage site. One aspect of Rhomboid proteolysis that differs significantly from processing by other I-CLiPs is that Rhomboid does not require preliminary ectodomain shedding, and is able to cleave full-length substrates with large extracellular domains [22,30].

Intramembranously-Cleaving Aspartyl Proteases: Presenilin, Signal Peptide Peptidase, and others

Presenilin (PS) and signal peptide peptidase (SPP) are members of an I-CLiP subfamily whose catalytic mechanism involves two aspartate residues, akin to classic aspartyl proteases [32]. Both are polytopic membrane proteins with two putative aspartate residues demarcating the catalytic site [33,34,35]. The observation that transition state analogues can mutually inhibit both enzymatic activities suggests that the two share similar active sites [36,37]. Though similarities between PS and SPP abound, differences have also been catalogued. Whereas PS is a member of a multiprotein complex, SPP can act alone [38]. The two proteases exhibit different substrate recognition profiles: PS cleaves type I single-TM proteins (cytosolically-oriented C-terminus), whereas SPP cleaves inversely-oriented type II TM proteins [32,39]. SPP and PS have conserved catalytic motifs (YD and LGxGD), each containing one of the active site aspartates, located in adjacent transmembrane regions. Intriguingly, the orientation of these two motifs are inverted in each of the two proteases, a property that may account for their unique *in vivo* substrate preferences [40] (Figure 3). SPP cleaves certain signal peptides with type II transmembrane orientation following their liberation from a preprotein by signal peptidase (SP) [41,42]. In addition to its role in the degradation of remnant signal peptides, SPP generates biologically-active peptides, such as HLA-E epitopes and calmodulin-dependent signaling peptides [43]. Furthermore, given its role in processing the HCV (hepatitis C virus) core protein [44] and the GB virus B core protein [45], SPP may be a useful therapeutic target in the prevention of certain viral infections. In analogy to S2P and Rhomboid, SPP requires helix-breaking residues for proteolysis [41], while its substrates appear to lack a well-defined recognition sequence [46].

Low-resolution structural data of γ -secretase allows us to speculate on the mechanism it employs to accomplish hydrolytic cleavage within the bilayer. An electron microscopic single particle reconstruction of the γ -secretase complex supports the notion of an intramembrane aqueous cavity through which water is able to penetrate the bilayer [47]. Li *et al.* suggest that a number of TM helices of PS provide a protein-surrounded cavity within the bilayer that is amenable to the presence of water. Studies employing cysteine-scanning mutagenesis and measurement of the accessibility of artificial cysteine residues to a hydrophilic reagent have corroborated the notion of an aqueous cavity within the interior of γ -secretase [48,49].

Profile of an Enigmatic Protease: γ -Secretase

γ -Secretase is perhaps the most intensely-studied intramembrane protease because of its critical role in the neuropathogenesis of Alzheimer's disease (AD) [50,51]. It processes the C-terminal fragment (CTF)-derived portion (C83 or C99) of the amyloid precursor protein (APP) within the membrane, liberating the beta-amyloid peptide (A β), which has a proclivity for aggregation, forming amyloid plaques in the central nervous system. Intermediates in the formation of these neuritic plaques are thought to be a major factor in the etiology of AD [52]. Despite its pivotal role in the most economically costly disease in the developed world [53,54], many basic features of the γ -secretase complex remain to be elucidated.

Composition, Assembly, and Subcellular Localization of γ -Secretase

Unlike other members of the family, γ -secretase requires multiple components — presenilin (PS), nicastrin (Nct), anterior pharynx defective-1 (Aph-1), and presenilin enhancer-2 (Pen-2) — for enzymatic activity both *in vivo* [55,56] and *in vitro* [57]. PS, a 9-pass TM protein [58, 59], is the catalytic core of the protease [60,61,35]; Nct, a single span membrane protein with a large, heavily-glycosylated extracellular domain, assists with substrate selection [62]; Aph-1, a 7-pass TM protein, promotes the assembly, stabilization, and traffic of the complex [63]; and Pen-2, a 2-pass TM protein, triggers PS endoproteolysis [64,65,66]. The precise molecular

stoichiometry of the complex was recently determined by Sato *et al.* to be 1:1:1:1 for PS:Nct:Aph-1:Pen-2 [67]. The relevance of non-essential cofactors remains uncertain.

Proper complex assembly and maturation requires all four components and appears to occur early in the secretory pathway [68,69], though the process has yet to be precisely localized. Assembly begins with the formation of a sub-complex between Nct and Aph-1, which is mediated by interactions between their respective TM domains [70]. Full-length presenilin stably associates with the initial Nct-Aph-1 complex [71,72] via an interaction between the extreme C-terminus of PS and the transmembrane domain of Nct [73-75]. Interaction with Pen-2 via TMD 4 of PS [76] then enables full-length presenilin to execute auto-endoproteolysis to form NTF and CTF heterodimers, which constitute the active protease [72,64-66]. The PS-NTF/CTF heterodimer is stabilized via an interaction with the C-terminal domain of Pen-2 [77].

The subcellular localization of γ -secretase has been a controversial issue, as residence has been reported in numerous compartments, including the endoplasmic reticulum (ER) [68], the Golgi/TGN [78], the endosome [79], the lysosome [80], the phagosome [81], the autophagic vacuole [82,83], and the plasma membrane [84,85]. Investigation using quantitative immunogold-electron microscopy reported PS1 localization at the plasma membrane, the ER, endosomes, vesicular-tubular clusters (VTCs), the nuclear envelope, and COPI-coated vesicles, while PS1 localization at the Golgi was minimal [86]. Despite the substantial concentration of PS in the ER, studies have demonstrated that γ -secretase attains an active proteolytic state in post-ER compartments [87]. The precise contribution of each of these locales to overall cellular γ -secretase activity has not been evaluated, though evidence suggests the plasma membrane and endosomes to be the principal sites of proteolysis [88].

Heterogeneity of γ -Secretase

PS and Aph-1 exist in multiple isoforms, each of which can be selectively incorporated into γ -secretase to generate an active protease, suggesting the possibility of distinct γ -secretase activities.

Two isoforms of PS — PS1 (the major isoform) and PS2 — exhibit a number of notable differences [89]: (1) there are strong phenotypic differences between PS1 — and PS2 — deficient systems; (2) isoform-specific expression levels are variable among different tissues; (3) each is incorporated into a proteolytic complex in a mutually exclusive manner; (4) each isoform exhibits differential susceptibility to certain γ the two isoforms differ in their ability to process APP CTFs. Furthermore, there is evidence for tissue-specific alternative splicing of the presenilin transcripts [90].

Three isoforms of Aph-1 have been identified in humans: Aph-1a (for which there are two splicing variants — Aph-1aS and Aph-1aL) and Aph-1b [91]. As with presenilin, tissue-specific expression patterns of Aph-1 have been documented [92], and evidence suggests these isoforms may be associated with functionally-distinct γ -secretase complexes [93]. Co-immunoprecipitation experiments implicated Aph-1aS, Aph-1aL, and Aph-1b in distinct γ -secretase complexes, each of which contained either PS1 or PS2, demonstrating the existence of six distinct proteolytic entities in mammals [94]. Functionality of each of the six combinatorial possibilities has recently been confirmed [95].

The factors regulating expression levels of the various isoforms and the biological significance of each of the six constitutionally-distinct complexes are not known. A greater understanding is necessary to determine whether functionally-distinct γ -secretase complexes exist at different stages of development or in different cell types, and if the variant complexes exhibit different substrate recognition properties or different intracellular traffic.

Ectodomain Shedding of γ -Secretase Substrates

The substrates for γ -secretase are generally derived from large precursor proteins that undergo a prerequisite ectodomain shedding event before being cleaved by γ -secretase [96]. Presenilin-dependent proteolysis therefore culminates a sequential proteolytic cascade that begins with the removal of a large extracellular fragment. This antecedent cleavage occurs in proximity to the membrane, such that the residual ectodomain is typically shorter than about thirty residues, a property that dramatically enhances substrate recognition by γ -secretase [96]. The enzymes that catalyze the ectodomain shedding event are termed *shedases* and include members of the disintegrin and metalloprotease (ADAM) family, such as ADAM-10 and ADAM-17; aspartyl proteases such as the β -site APP-cleaving enzymes (BACE1), and matrix metalloproteases (MMPs) [97]. ADAM-17, otherwise known as tumor necrosis factor- α (TNF α) converting enzyme (TACE) and ADAM-10 (and its ortholog *Kuzbanian*) are thought to exist predominantly at the cell surface, though intracellular shedding by these two proteases has also been documented (reviewed in [98]). Together with ADAM-9, these metalloproteases constitute “ α -secretase” activity, which processes APP in a non-amyloidogenic fashion [99]. BACE1 (the putative β -secretase that processes APP in the amyloidogenic pathway) is a transmembrane aspartic protease with maximal activity within the lumen of acidic organelles such as endosomes and also the Golgi apparatus (reviewed in [100]).

The ectodomain shedding event that generates PS substrates is often controlled by changes in higher-order structure, such as ligand-induced oligomerization (Figure 4). The binding of ligand or the *cis* homo- or hetero-dimerization of a receptor with another receptor (e.g., homophilic association of cadherins) has been observed to modulate ectodomain shedding for a large number of PS substrates. For instance, the binding of CD44 to hyaluronan oligosaccharides [191] or to a monoclonal antibody [192] can promote ectodomain shedding. The EphB2/ephrinB2 system involves reciprocal regulation in which both EphB2 (receptor) and ephrinB2 (ligand) are metalloproteolyzed upon *trans* interaction between the two proteins located on adjacent cell surfaces [136,137]. Furthermore, changes in substrate glycosylation state, which may affect ligand binding, are known to affect ectodomain shedding [168]. Pre-shedding dimerization or oligomerization has been reported for a number of γ -secretase substrates, including APP [193,194], APLP-1 and APLP-2 [194], syndecan-3 [195,196], and the homophilically-associating cell adhesion molecules (CAMs), including the cadherins [197] and protocadherins [198], nectin [199], and L1 [200].

Substrate Docking by γ -Secretase

Nicastrin (Nct), a single-span TM protein component of PS, was initially reported to be critical for the maturation of γ -secretase and for protease-substrate binding [201]. Later studies by Shah *et al.* cogently demonstrated that Nct assists the substrate recognition process [62]. Following preliminary ectodomain shedding of a γ -secretase substrate, the large Nct ectodomain binds to the substrate's free amino terminus. Chemical or antibody-mediated obstruction of a substrate's N-terminal amino functionality drastically inhibits substrate binding and γ -secretase activity. Shah *et al.* identified a region within the ectodomain of Nct — the DAP domain (*DIYGS* and *peptidase homologous region*) — to be critical for substrate recognition. Various mutations of a highly-conserved glutamate residue in the DAP domain abrogated substrate recognition, whereas mutation of this residue to an aspartate did not significantly interfere with PS activity. These results suggest that the carboxylate side chain of Nct E333 is involved in a direct interaction with the free N-terminal amino group of γ -secretase substrates (Figure 5) [62].

The interaction between Nct and the substrate N-terminus is involved in positioning the substrate into the initial substrate-binding site (or docking site), which is spatially distinct from the catalytic site. Multiple lines of evidence support the existence of physically-separated

docking and catalytic sites, including (1) the ability of γ -secretase to simultaneously bind a substrate and a transition state analogue (TSA) inhibitor [202,203]; (2) the observation that transition state analogues exhibit non-competitive inhibition [204,205]; and (3) FRET analysis demonstrating proximity between APP CTFs and PS while PS is bound to a TSA inhibitor [206].

An elegant study by Kornilova *et al.* demonstrated that the putative docking site and catalytic site are separated by a distance not exceeding three amino acid residues in length. A ten-residue helical peptide γ -secretase inhibitor (D-10) was reported to bind to the presenilin heterodimer interface. In contrast to TSA inhibitors, which allow simultaneous binding by substrates, D-10 prevented substrate binding, suggesting that it occupies the docking site. Whereas D-10 (at the docking site) and TSA inhibitors (at the active site) have been shown to simultaneously bind γ -secretase, D-13 (generated by a three residue extension of D-10) prevented binding of TSA inhibitors, suggesting that D-13 occupies both the docking site and the active site [207].

Such studies have led to a model of catalysis in which an interaction between Nct and the substrate N-terminus positions the substrate within the docking site, at the interface between PS NTF and CTF. Either physical translocation of the entire substrate or a kink within the TM region of the substrate enables the entire substrate or a portion thereof, respectively, to enter the catalytic site wherein peptide scission occurs (Fig. 5). Position x of the LGxGD catalytic motif located in TM7 of PS has been shown to be critical for substrate recognition [208].

The Role of Lipid Rafts in γ -Secretase Action

A large body of evidence has implicated cholesterol in the production of A β and the progression of AD. Cholesterol depletion in hippocampal neurons was shown to entirely abrogate A β production [209], while hypercholesterolemic mice have been shown to be afflicted with an accelerated amyloid pathology [210]. Cholesterol reduction (via application of the cholesterol-lowering agents known as statins) was shown to reduce BACE processing of the amyloid precursor protein (APP) in HEK 293 cells [211] and to reduce A β generation both in hippocampal neurons and in guinea pigs [212]. Epidemiological studies have correlated a reduction in the prevalence of dementia with the use of statins [213,214]. These effects may be related to disruption of lipid raft structures, wherein residence of BACE and γ -secretase has been reported [215-218]. Indeed, emerging evidence suggests an intimate connection between APP processing and lipid rafts (summarized in [219]). Note, however, the existence of contradictory epidemiological data [220], and the ambiguity characterizing the relationship between statins and A β , which could, for instance, be a consequence of altered protein isoprenylation [221].

Lipid rafts are highly-ordered membrane microdomains characterized by elevated levels of cholesterol, sphingolipids, glycolipids, saturated phospholipids, and glycosylphosphatidylinositol (GPI)-anchored proteins relative to the bulk environment of predominantly freely-mixing unsaturated phospholipids (reviewed in [222]). This particular arrangement imparts the property of resistance to solubilization by non-ionic detergents, such as Triton X-100, at reduced temperature, and delineates lipid rafts (also called detergent-resistant membranes, or DRMs) as a unique subphase within the context of the lipid bilayer. The functional importance of lipid rafts derives from their ability to sequester various proteins critical to biological processes such as signal transduction, membrane traffic, lateral membrane sorting [222], and, perhaps, regulated intramembrane proteolysis (reviewed in [223,224]).

Various reports have corroborated an intimate relationship between rafts and APP processing. APP has been reported to interact with resident raft proteins [225], and studies have demonstrated APP processing to be affected by ceramide, sphingolipids, glycosphingolipids,

and isoprenoids [226-230]. The critical dependence of amyloidogenic processing on lipid rafts [231,232] led Ehehalt *et al.* to postulate the existence of two separate pools of APP — a raft-associated one that is cleaved by BACE in an endocytosis-dependent manner, and a contingent that external to lipid rafts capable of undergoing non-amyloidogenic processing by α -secretase, most likely at the cell surface. Indeed, reduction of cholesterol levels has been shown to enhance non-amyloidogenic (α -secretase-mediated) processing of APP, an effect that correlates with augmented membrane fluidity and impaired APP internalization [233]. Vetrivel *et al.* have provided experimental support for a model in which γ -secretase and its substrates are compartmentalized into discrete membrane microdomains [234]. Distinct microdomain locales have also been reported for a γ -secretase substrate and its sheddase [235].

While it remains to be seen whether cleavage by other γ -secretase substrates is promoted by association with raft domains, it is very likely that mechanisms governing the movement of substrates between membrane microdomains are important. Several lines of evidence suggest that ligand-binding and oligomerization may control association of membrane proteins with lipid rafts. For example, translocation of the B-cell antigen receptor to lipid rafts is triggered by antigen-induced oligomerization, following which signal transduction events occur [236]. Similarly, the T-cell antigen receptor [237] and Fc ϵ RI [238] are recruited to rafts immediately subsequent to ligand binding. Engagement of tumor necrosis factor (TNF) receptor 1 by TNF α also triggers its association with rafts [239]. Binding of γ -secretase substrates, many of which function as transmembrane receptors, with cognate ligands may also trigger association with rafts. As discussed earlier, the ectodomain shedding event for a large number of γ -secretase substrates is triggered by ligand-binding or oligomerization, which suggests ectodomain shedding is linked to the promotion of affinity of certain substrates for rafts. Indeed, studies have reported the association of a number of γ -secretase substrates with lipid rafts and closely-related caveolae [240], including ApoER2 [241], CD44 [242], DCC [243], IGF-1R [244], LRP-1 [245], and N-cadherin [246]. Moreover, ligand-triggered association with rafts has been demonstrated for EphrinB1 [247], EphB2 [137], ErbB4 [248], GHR [249], HLA-A2 [250], and LRP-6 [251], while phosphorylation-dependent recruitment has been demonstrated for p75 [252].

Controlled Intracellular Trafficking as a Proteolytic Regulatory Mechanism — The Example of APP

APP traffic has been extensively studied; however, many aspects remain ambiguous and controversial. Traffic-controlled access of substrate to protease is dynamically regulated for several I-CLiPs (cf. Fig. 1), and will be surveyed in this section for the specific case of γ -secretase and APP (Figure 6).

Myriad proteins have been identified as mediators of APP traffic, many of which are members of the low density lipoprotein (LDL) receptor and phosphotyrosine binding (PTB) domain families. APP processing occurs at a number of locations as it is trafficked throughout the cell: prior to reaching the cell surface, at the cell surface, and following internalization from the cell surface, although the precise contribution of each pathway has not been investigated.

LDL-receptor related protein (LRP) has been implicated in the raft-association, internalization and amyloidogenic processing of APP [253,254,255]. LRP physically associates with uncleaved APP [256] and BACE1 [257], and therefore may be involved not only in the endocytosis of APP but in the presentation thereof to BACE1. LRP1b, which has a reduced rate of internalization relative to LRP, impairs APP endocytosis, enhances cell surface levels of APP, and stimulates non-amyloidogenic APP processing [258]. Another member of the LDL-receptor family, LR11/SorLA, has also been shown to mediate APP traffic (summarized in [259]). SorLA is believed to promote non-amyloidogenic processing of APP, as suggested by its reduced expression in the AD brain and the elevated production of A β upon ablation of

SorLA [260]. Amyloidogenic processing of APP is believed to occur primarily in the endosomal system following internalization of cell-surface APP. SorLA functions as a sorting receptor, and is thought to maintain APP in the Golgi, thereby preventing it from reaching the cell surface and subsequent endocytosis to the endosomes, thereby diverting it from the amyloidogenic pathway [261]. SorLA was later shown to interact directly with APP and BACE and to reduce APP-BACE interactions, suggesting that the reduction of amyloidogenic processing results from its interference with APP-BACE association [262,263]. A fourth member of the LDL-receptor family implicated in APP traffic is ApoER2, which, like LRP, binds APP and escorts it to lipid rafts; however, unlike LRP, ApoER2 reduces the internalization rate of APP, and elevates amyloidogenic processing at the cell surface [264]. F-spondin, an extracellular ligand of both APP and ApoER2, is believed to mediate a ternary complex with these two proteins, leading to enhancement of their respective cell surface levels and metalloprotease-mediated processing [109]. Intriguingly, each of these four transmembrane escort proteins are also cleaved by γ -secretase, which suggests a negative-feedback system, in which the escort protein is enzymatically degraded along with its cargo.

Various cytosolic adaptor proteins — the most prominent of which are members of the X11/Mint and Fe65 families — have been reported to bind the intracellular C-terminal YENPTY motif of APP (important for its traffic) via phosphotyrosine binding (PTB) domains, and thereby modulate processing of APP. Though the precise role of the X11/Mint proteins is presently unknown (reviewed in [265]), and controversial reports have been published [266], much data suggests that these proteins, along with synergistic contributions from Alcadeins [267] and Munc18a [268], inhibit production of A β , possibly by maintaining APP in an immature state in early compartments of the secretory pathway [269,270,271,272]. Recently, a role in APP traffic from the TGN has been established for the γ isoform of X11 [273].

The Fe65 family of adaptor proteins contain two PTB domains, the second of which (PTB2), binds to the APP family of proteins (APP, APLP1, APLP2) [274,275]. Fe65 and its homologues — Fe65-like (Fe65L) and Fe65L2 — have been reported to enhance A β production [276-278]. Although the mechanism by which Fe65 action is exerted is presently unknown, it may occur via concomitant interaction with LDL-receptor family members. Through its other PTB domain (PTB1), Fe65 can interact with a variety of proteins, including LRP1 and ApoER2, and can functionally link these two receptors to APP [279-282]. Fe65L1 has also been shown to enhance LRP degradation, suggesting that Fe65 family members may funnel APP and LRP in a tripartite complex toward secretase-containing compartments [283].

Disabled (Dab)-1, another PTB domain-containing protein binds to an NPxY motif in the cytosolic domain of APP, APLP1, APLP2, ApoER2, VLDLr, and LRP [279,284-286], each of which is a substrate for γ -secretase. Dab1 was reported to increase cell-surface levels of APP and ApoER2 and to elevate non-amyloidogenic APP processing [287], though elevated amyloidogenic processing has also been reported [288]. Numerous other adaptor proteins have been reported to bind APP and influence its processing, including c-Jun N-terminal kinase (JNK)-interacting protein-1 (JIP-1b) [289], PIN [290], ShcA and ShcC [291-292], PAT1 [293], BRI2 [294], and ARH [295].

Is γ -Secretase a Processive Protease?

Similar to other I-CLiPs [26,36,296], γ -secretase cleaves several substrates at multiple locations, including APLP-1, APP [103], CD44 [111], and Notch-1 [163]. APP is cleaved intramembranously at the γ -site, located in the center of the TMD near residue 40-42 (using the numbering of A β); the ϵ -site, located at the C-terminal end of the TMD near residue 49 [297]; and the ζ -site, located near residue 46 [298]. Investigation into the relationship between these various cleavage sites has demonstrated that A β 49 is likely the progenitor of A β 46, and that A β 46 is an intermediate precursor of A β 40/42 [299], giving rise to a sequential proteolytic

cascade model, in which small ~3 residue fragments are consecutively truncated from the C-terminus after an initial cleavage near the membrane-cytosol interface [300,301] (Figure 7). In agreement with this model, evidence suggests a sequential proteolysis of Notch, in which the S4 cleavage event, occurring near the middle of the Notch TMD, depends upon the S3 cleavage event, occurring near the membrane-cytosol interface [302]. Several studies [300, 301] have noted the orientation of APP cleavage sites on the same side of the transmembrane helix. Indeed, the periodicity of the ϵ -, ζ -, and γ -cleavage sites is similar to the periodicity of an α -helix, suggesting a model in which the C-terminus of an α -helical substrate is ratcheted into the catalytic site of γ -secretase, undergoing consecutive cleavage events that release a peptide fragment of approximately three or four amino acids in length.

Substrate Specificity of γ -Secretase

γ -Secretase is a very versatile protease, having already been reported to cleave nearly sixty unique type I transmembrane proteins (Fig. 4). Many of its substrates contain domains that are capable of translocating to the nucleus and modulating transcription of various genes [303]. Others do not appear to have a definitive signaling function, leading to γ -secretase's acquisition of the moniker "proteasome of the membrane" [304]. Potential pharmacological modulation of γ -secretase cleavage of C99 (the precursor to A β) [305], considered an important therapeutic target for AD [306], must not interfere with γ -secretases cleavage of its diverse collection of substrates.

Various studies have sought to define characteristics that distinguish γ -secretase substrates from peptides that are not cleaved, e.g., MUC1 [110]. Transmembrane domain orientation (type I—N-terminal-out) and ectodomain length (the average reported ectodomain length for γ -secretase substrates is slightly under 15 amino acids) were thought to be requisite features of all efficiently-processed substrates [96]; however, the discovery of peptides contradicting both of these principles suggests the importance of other features for substrate recognition by γ -secretase. Though the vast majority of γ -secretase substrates are type I TM proteins, type II TM proteins [307,308] as well as the glutamate receptor subunit 3 (GluR3), a multipass TM protein, have been reported to undergo PS-dependent processing [309]. Processing has been reported for full-length E-cadherin, which has an extracellular domain of more than 500 residues [132] as well as full-length VEGF receptor [188]. Lastly, γ -secretase does not appear to recognize a scissile bond by transmembrane depth, as it is capable of cleaving at sites throughout the transmembrane domain, at the membrane-cytosol interface [132,135], and in the cytosolic juxtamembranous region [159]. We have conducted an extensive bioinformatic examination of substrate primary, secondary, and quaternary structures to determine structural characteristics that predispose a substrate to γ -secretase proteolysis.

Recognition of Substrate Primary Structure by γ -Secretase

Sequence conservation among substrates is minimal, and mutations in substrates are apparently well tolerated by γ -secretase, as evidenced by a number of mutagenesis studies on the amyloid precursor protein [310-314] and other substrates. Nevertheless, there are examples of single point mutations that entirely abolish γ -secretase cleavage, suggesting that while the enzyme is promiscuous, it requires certain sequence or structural characteristics for proper substrate recognition. Single point mutations of the ErbB4 receptor tyrosine kinase (V673I) and the Notch-1 receptor (V1744G), for instance, are known to abrogate proteolysis [139,315]. In both cases, the mutated valine residue is located immediately adjacent to the site of cleavage. Many γ -secretase substrates contain a similarly-positioned valine, which, though critical for the cleavage of Notch-1 and ErbB4, has been demonstrated to be dispensable for the cleavage of other substrates, including APP [310], CD43 [110], and DCC [126]. Hence, the importance of primary structure is equivocal, and recognition likely involves factors at higher levels of protein structure.

Recognition of Substrate Secondary Structure

Proteolysis by other I-CLiPs is enhanced by and often requires helix-destabilizing residues. To determine if a similar requirement exists for γ -secretase proteolysis, we performed secondary structural predictions on all substrates with known primary cleavage sites (Figure 8). The results suggest that helix destabilization may be important for presenilin-mediated proteolysis. To our knowledge, this is the first such demonstration of the potential relevance of transmembrane helix destabilization for γ -secretase proteolysis. Cleavage appears to most commonly occur near the C-terminal end of the transmembrane helix just inside the membrane-cytosolic interface (Fig. 4).

Recognition of Substrate Higher-Order Structure by γ -Secretase

A number of γ -secretase substrates — syndecan-3 [195], E-cadherin [319], N-cadherin [320], ErbB4 [321], APP [322], PTP κ , and PTP μ [323] — dimerize via transmembrane domain interactions. Several substrates (ErbB4, IGF-1R, CSF-1R, VEGF-1R, EphB2) are receptor tyrosine kinases (RTKs), which are known to dimerize in response to ligand binding [324]. Mutationally-induced promotion of APP homodimerization resulted in substantial elevation of A β production, suggesting that dimerization may be a direct regulatory factor in the proteolytic processing of APP [193]. In addition to ectodomain dimerization interfaces, a particular motif within the C99 TMD — GxxxG — mediates homodimerization, and mutations affecting the dimerization strength of this motif alter γ -secretase cleavage precision, but not efficiency. Interestingly, more than 25% of γ -secretase substrates contain the GxxxG pentapeptide — a canonical transmembrane dimerization motif [325-327] — in their transmembrane domain (cf. Fig. 4). Inhibition of C99 dimerization by mutating its GxxxG motifs was shown to specifically reduce production of longer forms of A β (e.g., A β 42) and increased production of shorter forms of A β (e.g., A β 35, A β 38) [322]. These observations have led to an expansion of the processive proteolysis model proposed by Qi-Takahara, such that presenilin proteolysis removes consecutive fragments from the exposed C-terminus of APP until cleavage reaches a certain distance from the dimerization motif, whereupon cleavage terminates and A β 40/42 is released. Disruption or attenuation of the dimerization interface allows continued proteolysis of APP, with the concomitant release of shorter A β fragments. According to this model, the terminal cleavage point is determined by the location and strength of the transmembrane dimerization interface [322]. Note that oligomerization-dependent control of proteolysis is unlikely to apply to all γ -secretase substrates, as demonstrated for the Notch receptor [165], suggesting the existence of multiple proteolytic regulatory mechanisms.

Perspectives

Common themes have begun to emerge among the evolutionarily-diverse class of proteases known as I-CLiPs. A regulated event such as ligand binding or ectodomain shedding precipitates complex subcellular traffic events or movement between membrane microdomains, following which the formerly separated protease and substrate come into contact. Often, the proteolytic cleavage that ensues is not merely degradative in nature, but initiates a signaling cascade that can impact genomic expression, communicate information to other cells, effect cellular homeostasis, or nucleate pathological events. These peculiar proteases have co-opted classical protease motifs. Their sequence specificity is typically quite loose, and factors beyond the primary level of protein structure, particularly transmembrane helix destabilization, appear more important for substrate recognition and proteolysis.

Although much has been learned, many basic questions remain unanswered. The substrate/enzyme stoichiometry, relevance of additional cofactors, and subcellular localization and traffic of γ -secretase remain ill-defined. The traffic between subcellular compartments and membrane microdomains for C99 and other γ -secretase substrates — a critical facet of

proteolytic regulation — requires much additional investigation. While correlations have been reported the discovery of causal factors regulating substrate traffic and ectodomain shedding has been limited. Indeed, for C99 it remains unclear which trafficking and/or enzymic properties limit the rate of amyloid- β production. The processive model of intramembranous cleavage also remains highly suppositional. Such basic issues require continued attention to acquire a deeper understanding of the various physiological and pathophysiological events mediated or influenced by γ -secretase proteolysis. The clinical utility of agents that modulate γ -secretase activity, considered a viable therapeutic avenue for the prevention and treatment of Alzheimer's disease, will be enhanced by an elucidation of these fundamental questions.

Acknowledgements

The authors thank Drs. Jens Meiler and Jonathan Sheehan for their assistance in secondary structure prediction and multiple sequence alignments using as-yet-unpublished software developed by the Meiler lab. Additionally, the authors thank Professor Richard A. Kahn of Emory University for his very helpful comments on the original version of this review. The authors were supported by US NIH grant R21 AG026581 and by Alzheimer's Association grant IIRG-07-59379.

References

1. Wolfe MS, Kopan R. Intramembrane proteolysis: theme and variations. *Science* 2004;305:1119–1123. [PubMed: 15326347]
2. Golde TE, Eckman CB. Physiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis. *Sci STKE* 2003;2003:RE4. [PubMed: 12621149]
3. Makinoshima H, Glickman MS. Site-2 proteases in prokaryotes: regulated intramembrane proteolysis expands to microbial pathogenesis. *Microbes Infect* 2006;8:1882–1888. [PubMed: 16731018]
4. McPherson R, Gauthier A. Molecular regulation of SREBP function: the Insig-SCAP connection and isoform-specific modulation of lipid synthesis. *Biochem Cell Biol* 2004;82:201–211. [PubMed: 15052338]
5. Sakai J, Duncan EA, Rawson RB, Hua X, Brown MS, Goldstein JL. Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment. *Cell* 1996;85:1037–1046. [PubMed: 8674110]
6. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *Proc Natl Acad Sci U S A* 1999;96:11041–11048. [PubMed: 10500120]
7. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* 1997;89:331–340. [PubMed: 9150132]
8. DeBose-Boyd RA, Brown MS, Li WP, Nohturfft A, Goldstein JL, Espenshade PJ. Transport-dependent proteolysis of SREBP: relocation of site-1 protease from Golgi to ER obviates the need for SREBP transport to Golgi. *Cell* 1999;99:703–712. [PubMed: 10619424]
9. Hua X, Nohturfft A, Goldstein JL, Brown MS. Sterol resistance in CHO cells traced to point mutation in SREBP cleavage-activating protein. *Cell* 1996;87:415–426. [PubMed: 8898195]
10. Sakai J, Nohturfft A, Cheng D, Ho YK, Brown MS, Goldstein JL. Identification of complexes between the COOH-terminal domains of sterol regulatory element-binding proteins (SREBPs) and SREBP cleavage-activating protein. *J Biol Chem* 1997;272:20213–20221. [PubMed: 9242699]
11. Sun LP, Li L, Goldstein JL, Brown MS. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. *J Biol Chem* 2005;280:26483–26490. [PubMed: 15899885]
12. Goldstein JL, DeBose-Boyd RA, Brown MS. Protein sensors for membrane sterols. *Cell* 2006;124:35–46. [PubMed: 16413480]
13. Radhakrishnan A, Ikeda Y, Kwon HJ, Brown MS, Goldstein JL. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. *Proc Natl Acad Sci U S A* 2007;104:6511–6518. [PubMed: 17428920]
14. Espenshade PJ, Li WP, Yabe D. Sterols block binding of COPII proteins to SCAP, thereby controlling SCAP sorting in ER. *Proc Natl Acad Sci U S A* 2002;99:11694–11699. [PubMed: 12193656]

15. Sakai J, Nohturfft A, Goldstein JL, Brown MS. Cleavage of sterol regulatory element-binding proteins (SREBPs) at site-1 requires interaction with SREBP cleavage-activating protein. Evidence from in vivo competition studies. *J Biol Chem* 1998;273:5785–5793. [PubMed: 9488713]
16. Hua X, Sakai J, Brown MS, Goldstein JL. Regulated cleavage of sterol regulatory element binding proteins requires sequences on both sides of the endoplasmic reticulum membrane. *J Biol Chem* 1996;271:10379–10384. [PubMed: 8626610]
17. Sakai J, Rawson RB, Espenshade PJ, Cheng D, Seegmiller AC, Goldstein JL, Brown MS. Molecular identification of the sterol-regulated luminal protease that cleaves SREBPs and controls lipid composition of animal cells. *Mol Cell* 1998;2:505–514. [PubMed: 9809072]
18. Duncan EA, Dave UP, Sakai J, Goldstein JL, Brown MS. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteine panning. *J Biol Chem* 1998;273:17801–17809. [PubMed: 9651382]
19. Ye J, Dave UP, Grishin NV, Goldstein JL, Brown MS. Asparagine-proline sequence within membrane-spanning segment of SREBP triggers intramembrane cleavage by site-2 protease. *Proc Natl Acad Sci U S A* 2000;97:5123–5128. [PubMed: 10805775]
20. Urban S. Rhomboid proteases: conserved membrane proteases with divergent biological functions. *Genes Dev* 2006;20:3054–3068. [PubMed: 17114579]
21. Lee JR, Urban S, Garvey CF, Freeman M. Regulated intracellular ligand transport and proteolysis control EGF signal activation in *Drosophila*. *Cell* 2001;107:161–171. [PubMed: 11672524]
22. Lemberg MK, Menendez J, Misik A, Garcia M, Koth CM, Freeman M. Mechanism of intramembrane proteolysis investigated with purified rhomboid proteases. *EMBO J* 2005;24:464–472. [PubMed: 15616571]
23. Wang Y, Zhang Y, Ha Y. Crystal structure of a rhomboid family intramembrane protease. *Nature* 2006;444:179–180. [PubMed: 17051161]
24. Ben-Shem A, Fass D, Bibi E. Structural basis for intramembrane proteolysis by rhomboid serine proteases. *Proc Natl Acad Sci U S A* 2007;104:462–466. [PubMed: 17190827]
25. Wu Z, Yan N, Feng L, Oberstein A, Yan H, Baker RP, Gu L, Jeffrey PD, Urban S, Shi Y. Structural analysis of a rhomboid family intramembrane protease reveals a gating mechanism for substrate entry. *Nat Struct Mol Biol* 2006;13:1084–1091. [PubMed: 17099694]
26. Baker RP, Young K, Feng L, Shi Y, Urban S. Enzymatic analysis of a rhomboid intramembrane protease implicates transmembrane helix 5 as the lateral substrate gate. *Proc Natl Acad Sci U S A* 2007;104:8257–8262. [PubMed: 17463085]
27. Lieberman RL, Wolfe MS. Membrane-embedded protease poses for photoshoot. *Proc Natl Acad Sci U S A* 2007;104:401–402. [PubMed: 17213330]
28. Freeman M. Structural biology: enzyme theory holds water. *Nature* 2006;444:153–155. [PubMed: 17051148]
29. Tsruya R, Schlesinger A, Reich A, Gabay L, Sapir A, Shilo BZ. Intracellular trafficking by Star regulates cleavage of the *Drosophila* EGF receptor ligand Spitz. *Genes Dev* 2002;16:222–234. [PubMed: 11799065]
30. Urban S, Freeman M. Substrate specificity of rhomboid intramembrane proteases is governed by helix-breaking residues in the substrate transmembrane domain. *Mol Cell* 2003;11:1425–1434. [PubMed: 12820957]
31. Akiyama Y, Maegawa S. Sequence features of substrates required for cleavage by GlpG, an *Escherichia coli* rhomboid protease. *Mol Microbiol* 2007;64:1028–1037. [PubMed: 17501925]
32. Martoglio B, Golde TE. Intramembrane-cleaving aspartic proteases and disease: presenilins, signal peptide peptidase and their homologs. *Hum Mol Genet* 2003;12(Spec No 2):R201–206. [PubMed: 12966028]
33. Weihofen A, Binns K, Lemberg MK, Ashman K, Martoglio B. Identification of signal peptide peptidase, a presenilin-type aspartic protease. *Science* 2002;296:2215–2218. [PubMed: 12077416]
34. Steiner H, Kostka M, Romig H, Basset G, Pesold B, Hardy J, Capell A, Meyn L, Grim ML, Baumeister R, Fichteler K, Haass C. Glycine 384 is required for presenilin-1 function and is conserved in bacterial polytopic aspartyl proteases. *Nat Cell Biol* 2000;2:848–851. [PubMed: 11056541]

35. Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. *Nature* 1999;398:513–517. [PubMed: 10206644]
36. Sato T, Nyborg AC, Iwata N, Diehl TS, Saido TC, Golde TE, Wolfe MS. Signal peptide peptidase: biochemical properties and modulation by nonsteroidal antiinflammatory drugs. *Biochemistry* 2006;45:8649–8656. [PubMed: 16834339]
37. Weihofen A, Lemberg MK, Friedmann E, Rueeger H, Schmitz A, Paganetti P, Rovelli G, Martoglio B. Targeting presenilin-type aspartic protease signal peptide peptidase with gamma-secretase inhibitors. *J Biol Chem* 2003;278:16528–16533. [PubMed: 12621027]
38. Narayanan S, Sato T, Wolfe MS. A C-terminal region of signal peptide peptidase defines a functional domain for intramembrane aspartic protease catalysis. *J Biol Chem* 2007;282:20172–20179. [PubMed: 17517891]
39. Xia W, Wolfe MS. Intramembrane proteolysis by presenilin and presenilin-like proteases. *J Cell Sci* 2003;116:2839–2844. [PubMed: 12808018]
40. Nyborg AC, Jansen K, Ladd TB, Fauq A, Golde TE. A signal peptide peptidase (SPP) reporter activity assay based on the cleavage of type II membrane protein substrates provides further evidence for an inverted orientation of the SPP active site relative to presenilin. *J Biol Chem* 2004;279:43148–43156. [PubMed: 15252014]
41. Lemberg MK, Martoglio B. Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis. *Mol Cell* 2002;10:735–744. [PubMed: 12419218]
42. Dev KK, Chatterjee S, Osinde M, Stauffer D, Morgan H, Kobialko M, Dengler U, Rueeger H, Martoglio B, Rovelli G. Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals. *Eur J Pharmacol* 2006;540:10–17. [PubMed: 16697367]
43. Weihofen A, Martoglio B. Intramembrane-cleaving proteases: controlled liberation of proteins and bioactive peptides. *Trends Cell Biol* 2003;13:71–78. [PubMed: 12559757]
44. Ait-Goughoulte M, Hourieux C, Patient R, Trassard S, Brand D, Roingeard P. Core protein cleavage by signal peptide peptidase is required for hepatitis C virus-like particle assembly. *J Gen Virol* 2006;87:855–860. [PubMed: 16528035]
45. Targett-Adams P, Schaller T, Hope G, Lanford RE, Lemon SM, Martin A, McLauchlan J. Signal peptide peptidase cleavage of GB virus B core protein is required for productive infection in vivo. *J Biol Chem* 2006;281:29221–29227. [PubMed: 16882659]
46. Ma HC, Ku YY, Hsieh YC, Lo SY. Characterization of the cleavage of signal peptide at the C-terminus of hepatitis C virus core protein by signal peptide peptidase. *J Biomed Sci* 2007;14:31–41. [PubMed: 17237979]
47. Lazarov VK, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. Electron microscopic structure of purified, active gamma-secretase reveals an aqueous intramembrane chamber and two pores. *Proc Natl Acad Sci U S A* 2006;103:6889–6894. [PubMed: 16636269]
48. Tolia A, Chavez-Gutierrez L, De Strooper B. Contribution of presenilin transmembrane domains 6 and 7 to a water-containing cavity in the gamma-secretase complex. *J Biol Chem* 2006;281:27633–27642. [PubMed: 16844686]
49. Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of gamma-secretase probed by the accessibility of substituted cysteines. *J Neurosci* 2006;26:12081–12088. [PubMed: 17108181]
50. Brunkan AL, Goate AM. Presenilin function and gamma-secretase activity. *J Neurochem* 2005;93:769–792. [PubMed: 15857382]
51. Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. *Biochemistry* 2006;45:7931–7939. [PubMed: 16800619]
52. Pastorino L, Lu KP. Pathogenic mechanisms in Alzheimer's disease. *Eur J Pharmacol* 2006;545:29–38. [PubMed: 16904664]
53. Mount C, Downton C. Alzheimer disease: progress or profit? *Nat Med* 2006;12:780–784. [PubMed: 16829947]
54. Jellinger KA. Alzheimer 100--highlights in the history of Alzheimer research. *J Neural Transm* 2006;113:1603–1623. [PubMed: 17039299]

55. Kimberly WT, LaVoie MJ, Ostaszewski BL, Ye W, Wolfe MS, Selkoe DJ. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. *Proc Natl Acad Sci U S A* 2003;100:6382–6387. [PubMed: 12740439]
56. Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. *Nat Cell Biol* 2003;5:486–488. [PubMed: 12679784]
57. Fraering PC, Ye W, Strub JM, Dolios G, LaVoie MJ, Ostaszewski BL, van Dorsselaer A, Wang R, Selkoe DJ, Wolfe MS. Purification and characterization of the human gamma-secretase complex. *Biochemistry* 2004;43:9774–9789. [PubMed: 15274632]
58. Laudon H, Hansson EM, Melen K, Bergman A, Farmery MR, Winblad B, Lendahl U, von Heijne G, Naslund J. A nine-transmembrane domain topology for presenilin 1. *J Biol Chem* 2005;280:35352–35360. [PubMed: 16046406]
59. Spasic D, Tolia A, Dillen K, Baert V, De Strooper B, Vrijens S, Annaert W. Presenilin-1 maintains a nine-transmembrane topology throughout the secretory pathway. *J Biol Chem* 2006;281:26569–26577. [PubMed: 16846981]
60. Li YM, Xu M, Lai MT, Huang Q, Castro JL, DiMuzio-Mower J, Harrison T, Lellis C, Nadin A, Neduvilil JG, Register RB, Sardana MK, Shearman MS, Smith AL, Shi XP, Yin KC, Shafer JA, Gardell SJ. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. *Nature* 2000;405:689–694. [PubMed: 10864326]
61. Esler WP, Kimberly WT, Ostaszewski BL, Diehl TS, Moore CL, Tsai JY, Rahmati T, Xia W, Selkoe DJ, Wolfe MS. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. *Nat Cell Biol* 2000;2:428–434. [PubMed: 10878808]
62. Shah S, Lee SF, Tabuchi K, Hao YH, Yu C, LaPlant Q, Ball H, Dann CE 3rd, Sudhof T, Yu G. Nicastrin functions as a gamma-secretase-substrate receptor. *Cell* 2005;122:435–447. [PubMed: 16096062]
63. Niimura M, Isoo N, Takasugi N, Tsuruoka M, Ui-Tei K, Saigo K, Morohashi Y, Tomita T, Iwatsubo T. Aph-1 contributes to the stabilization and trafficking of the gamma-secretase complex through mechanisms involving intermolecular and intramolecular interactions. *J Biol Chem* 2005;280:12967–12975. [PubMed: 15644323]
64. Luo WJ, Wang H, Li H, Kim BS, Shah S, Lee HJ, Thinakaran G, Kim TW, Yu G, Xu H. PEN-2 and APH-1 coordinately regulate proteolytic processing of presenilin 1. *J Biol Chem* 2003;278:7850–7854. [PubMed: 12522139]
65. Thinakaran G, Borchelt DR, Lee MK, Slunt HH, Spitzer L, Kim G, Ratovitsky T, Davenport F, Nordstedt C, Seeger M, Hardy J, Levey AI, Gandy SE, Jenkins NA, Copeland NG, Price DL, Sisodia SS. Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo. *Neuron* 1996;17:181–190. [PubMed: 8755489]
66. Brunkan AL, Martinez M, Walker ES, Goate AM. Presenilin endoproteolysis is an intramolecular cleavage. *Mol Cell Neurosci* 2005;29:65–73. [PubMed: 15866047]
67. Sato T, Diehl TS, Narayanan S, Funamoto S, Ihara Y, De Strooper B, Steiner H, Haass C, Wolfe MS. Active {gamma}-Secretase Complexes Contain Only One of Each Component. *J Biol Chem* 2007;282:33985–33993. [PubMed: 17911105]
68. Kim SH, Yin YI, Li YM, Sisodia SS. Evidence that assembly of an active gamma-secretase complex occurs in the early compartments of the secretory pathway. *J Biol Chem* 2004;279:48615–48619. [PubMed: 15456788]
69. Capell A, Behr D, Prokop S, Steiner H, Kaether C, Shearman MS, Haass C. Gamma-secretase complex assembly within the early secretory pathway. *J Biol Chem* 2005;280:6471–6478. [PubMed: 15591316]
70. LaVoie MJ, Fraering PC, Ostaszewski BL, Ye W, Kimberly WT, Wolfe MS, Selkoe DJ. Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin. *J Biol Chem* 2003;278:37213–37222. [PubMed: 12857757]
71. Gu Y, Chen F, Sanjo N, Kawarai T, Hasegawa H, Duthie M, Li W, Ruan X, Luthra A, Mount HT, Tandon A, Fraser PE, George-Hyslop P. APH-1 interacts with mature and immature forms of presenilins and nicastrin and may play a role in maturation of presenilin.nicastrin complexes. *J Biol Chem* 2003;278:7374–7380. [PubMed: 12471034]

72. Takasugi N, Tomita T, Hayashi I, Tsuruoka M, Niimura M, Takahashi Y, Thinakaran G, Iwatsubo T. The role of presenilin cofactors in the gamma-secretase complex. *Nature* 2003;422:438–441. [PubMed: 12660785]
73. Tomita T, Takikawa R, Koyama A, Morohashi Y, Takasugi N, Saido TC, Maruyama K, Iwatsubo T. C terminus of presenilin is required for overproduction of amyloidogenic Abeta42 through stabilization and endoproteolysis of presenilin. *J Neurosci* 1999;19:10627–10634. [PubMed: 10594046]
74. Kaether C, Capell A, Edbauer D, Winkler E, Novak B, Steiner H, Haass C. The presenilin C-terminus is required for ER-retention, nicastrin-binding and gamma-secretase activity. *EMBO J* 2004;23:4738–4748. [PubMed: 15549135]
75. Bergman A, Laudon H, Winblad B, Lundkvist J, Näslund J. The extreme C terminus of presenilin 1 is essential for gamma-secretase complex assembly and activity. *J Biol Chem* 2004;279:45564–45572. [PubMed: 15322123]
76. Watanabe N, Tomita T, Sato C, Kitamura T, Morohashi Y, Iwatsubo T. Pen-2 is incorporated into the gamma-secretase complex through binding to transmembrane domain 4 of presenilin 1. *J Biol Chem* 2005;280:41967–41975. [PubMed: 16234244]
77. Prokop S, Shirota K, Edbauer D, Haass C, Steiner H. Requirement of PEN-2 for stabilization of the presenilin N-/C-terminal fragment heterodimer within the gamma-secretase complex. *J Biol Chem* 2004;279:23255–23261. [PubMed: 15039426]
78. Baulac S, LaVoie MJ, Kimberly WT, Strahle J, Wolfe MS, Selkoe DJ, Xia W. Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. *Neurobiol Dis* 2003;14:194–204. [PubMed: 14572442]
79. Lah JJ, Levey AI. Endogenous presenilin-1 targets to endocytic rather than biosynthetic compartments. *Mol Cell Neurosci* 2000;16:111–126. [PubMed: 10924255]
80. Pasternak SH, Bagshaw RD, Guiral M, Zhang S, Ackerley CA, Pak BJ, Callahan JW, Mahuran DJ. Presenilin-1, nicastrin, amyloid precursor protein, and gamma-secretase activity are co-localized in the lysosomal membrane. *J Biol Chem* 2003;278:26687–26694. [PubMed: 12736250]
81. Jutras I, Laplante A, Boulais J, Brunet S, Thinakaran G, Desjardins M. Gamma-secretase is a functional component of phagosomes. *J Biol Chem* 2005;280:36310–36317. [PubMed: 16103123]
82. Yu WH, Kumar A, Peterhoff C, Shapiro Kulnane L, Uchiyama Y, Lamb BT, Cuervo AM, Nixon RA. Autophagic vacuoles are enriched in amyloid precursor protein-secretase activities: implications for beta-amyloid peptide over-production and localization in Alzheimer's disease. *Int J Biochem Cell Biol* 2004;36:2531–2540. [PubMed: 15325590]
83. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Näslund J, Mathews PM, Cataldo AM, Nixon RA. Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 2005;171:87–98. [PubMed: 16203860]
84. Ray WJ, Yao M, Mumm J, Schroeter EH, Saftig P, Wolfe M, Selkoe DJ, Kopan R, Goate AM. Cell surface presenilin-1 participates in the gamma-secretase-like proteolysis of Notch. *J Biol Chem* 1999;274:36801–36807. [PubMed: 10593990]
85. Chyung JH, Raper DM, Selkoe DJ. Gamma-secretase exists on the plasma membrane as an intact complex that accepts substrates and effects intramembrane cleavage. *J Biol Chem* 2005;280:4383–4392. [PubMed: 15569674]
86. Rechards M, Xia W, Oorschot VM, Selkoe DJ, Klumperman J. Presenilin-1 exists in both pre- and post-Golgi compartments and recycles via COPI-coated membranes. *Traffic* 2003;4:553–565. [PubMed: 12839498]
87. Cupers P, Bentahir M, Craessaerts K, Orlans I, Vanderstichele H, Saftig P, De Strooper B, Annaert W. The discrepancy between presenilin subcellular localization and gamma-secretase processing of amyloid precursor protein. *J Cell Biol* 2001;154:731–740. [PubMed: 11502763]
88. Kaether C, Schmitt S, Willem M, Haass C. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. *Traffic* 2006;7:408–415. [PubMed: 16536739]

89. Lai MT, Chen E, Crouthamel MC, DiMuzio-Mower J, Xu M, Huang Q, Price E, Register RB, Shi XP, Donoviel DB, Bernstein A, Hazuda D, Gardell SJ, Li YM. Presenilin-1 and presenilin-2 exhibit distinct yet overlapping gamma-secretase activities. *J Biol Chem* 2003;278:22475–22481. [PubMed: 12684521]
90. TandonA FraserP The presenilins. *Genome Biol* 20023, reviews. 3014.13014.9
91. Lee SF, Shah S, Li H, Yu C, Han W, Yu G. Mammalian APh-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch. *J Biol Chem* 2002;277:45013–45019. [PubMed: 12297508]
92. Hebert SS, Serneels L, DeJaegere T, Horre K, Dabrowski M, Baert V, Annaert W, Hartmann D, De Strooper B. Coordinated and widespread expression of gamma-secretase in vivo: evidence for size and molecular heterogeneity. *Neurobiol Dis* 2004;17:260–272. [PubMed: 15474363]
93. Serneels L, DeJaegere T, Craessaerts K, Horre K, Jorissen E, Tousseyn T, Hebert S, Coolen M, Martens G, Zwijsen A, Annaert W, Hartmann D, De Strooper B. Differential contribution of the three Aph1 genes to gamma-secretase activity in vivo. *Proc Natl Acad Sci U S A* 2005;102:1719–1724. [PubMed: 15665098]
94. Shirotani K, Edbauer D, Prokop S, Haass C, Steiner H. Identification of distinct gamma-secretase complexes with different APh-1 variants. *J Biol Chem* 2004;279:41340–41345. [PubMed: 15286082]
95. Shirotani K, Tomioka M, Kremmer E, Haass C, Steiner H. Pathological activity of familial Alzheimer's disease-associated mutant presenilin can be executed by six different gamma-secretase complexes. *Neurobiol Dis* 2007;27:102–107. [PubMed: 17560791]
96. Struhl G, Adachi A. Requirements for presenilin-dependent cleavage of notch and other transmembrane proteins. *Mol Cell* 2000;6:625–636. [PubMed: 11030342]
97. Lichtenthaler SF, Steiner H. Sheddases and intramembrane-cleaving proteases: RIPPers of the membrane. Symposium on regulated intramembrane proteolysis. *EMBO Rep* 2007;8:537–541. [PubMed: 17496832]
98. Huovila AP, Turner AJ, Pelto-Huikko M, Karkkainen I, Ortiz RM. Shedding light on ADAM metalloproteinases. *Trends Biochem Sci* 2005;30:413–422. [PubMed: 15949939]
99. Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, Ishiura S. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. *Biochem Biophys Res Commun* 2003;301:231–235. [PubMed: 12535668]
100. Vassar R. BACE1: the beta-secretase enzyme in Alzheimer's disease. *J Mol Neurosci* 2004;23:105–114. [PubMed: 15126696]
101. Araki Y, Miyagi N, Kato N, Yoshida T, Wada S, Nishimura M, Komano H, Yamamoto T, De Strooper B, Yamamoto K, Suzuki T. Coordinated metabolism of Alcadin and amyloid beta-protein precursor regulates FE65-dependent gene transactivation. *J Biol Chem* 2004;279:24343–24354. [PubMed: 15037614]
102. Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D'Adamio L. Processing of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates transcription. *J Biol Chem* 2002;277:44195–44201. [PubMed: 12228233]
103. Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther K. The proteolytic processing of the amyloid precursor protein gene family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation. *J Biol Chem* 2004;279:18146–18156. [PubMed: 14970212]
104. Endres K, Postina R, Schroeder A, Mueller U, Fahrenholz F. Shedding of the amyloid precursor protein-like protein APLP2 by disintegrin-metalloproteinases. *FEBS J* 2005;272:5808–5820. [PubMed: 16279945]
105. Hoe HS, Rebeck GW. Regulation of ApoE receptor proteolysis by ligand binding. *Brain Res Mol Brain Res* 2005;137:31–39. [PubMed: 15950758]
106. May P, Bock HH, Nimpf J, Herz J. Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase. *J Biol Chem* 2003;278:37386–37392. [PubMed: 12871934]
107. Xia W, Zhang J, Ostaszewski BL, Kimberly WT, Seubert P, Koo EH, Shen J, Selkoe DJ. Presenilin 1 regulates the processing of beta-amyloid precursor protein C-terminal fragments and the

generation of amyloid beta-protein in endoplasmic reticulum and Golgi. *Biochemistry* 1998;37:16465–16471. [PubMed: 9843412]

108. Li Q, Sudhof TC. Cleavage of amyloid-beta precursor protein and amyloid-beta precursor-like protein by BACE 1. *J Biol Chem* 2004;279:10542–10550. [PubMed: 14699153]
109. Hoe HS, Wessner D, Beffert U, Becker AG, Matsuoka Y, Rebeck GW. F-spondin interaction with the apolipoprotein E receptor ApoEr2 affects processing of amyloid precursor protein. *Mol Cell Biol* 2005;25:9259–9268. [PubMed: 16227578]
110. Andersson CX, Fernandez-Rodriguez J, Laos S, Baeckstrom D, Haass C, Hansson GC. Shedding and gamma-secretase-mediated intramembrane proteolysis of the mucin-type molecule CD43. *Biochem J* 2005;387:377–384. [PubMed: 15540986]
111. Lammich S, Okochi M, Takeda M, Kaether C, Capell A, Zimmer AK, Edbauer D, Walter J, Steiner H, Haass C. Presenilin-dependent intramembrane proteolysis of CD44 leads to the liberation of its intracellular domain and the secretion of an Abeta-like peptide. *J Biol Chem* 2002;277:44754–44759. [PubMed: 12223485]
112. Okamoto I, Kawano Y, Murakami D, Sasayama T, Araki N, Miki T, Wong AJ, Saya H. Proteolytic release of CD44 intracellular domain and its role in the CD44 signaling pathway. *J Cell Biol* 2001;155:755–762. [PubMed: 11714729]
113. Murakami D, Okamoto I, Nagano O, Kawano Y, Tomita T, Iwatsubo T, De Strooper B, Yumoto E, Saya H. Presenilin-dependent gamma-secretase activity mediates the intramembraneous cleavage of CD44. *Oncogene* 2003;22:1511–1516. [PubMed: 12629514]
114. Okamoto I, Kawano Y, Tsuiki H, Sasaki J, Nakao M, Matsumoto M, Suga M, Ando M, Nakajima M, Saya H. CD44 cleavage induced by a membrane-associated metalloprotease plays a critical role in tumor cell migration. *Oncogene* 1999;18:1435–1446. [PubMed: 10050880]
115. Bazil V, Horejsi V. Shedding of the CD44 adhesion molecule from leukocytes induced by anti-CD44 monoclonal antibody simulating the effect of a natural receptor ligand. *J Immunol* 1992;149:747–753. [PubMed: 1634766]
116. Bazil V, Strominger JL. Metalloprotease and serine protease are involved in cleavage of CD43, CD44, and CD16 from stimulated human granulocytes. Induction of cleavage of L-selectin via CD16. *J Immunol* 1994;152:1314–1322. [PubMed: 7507963]
117. Liu D, Sy MS. Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain. *J Immunol* 1997;159:2702–2711. [PubMed: 9300690]
118. Wilhelmsen K, van der Geer P. Phorbol 12-myristate 13-acetate-induced release of the colony-stimulating factor 1 receptor cytoplasmic domain into the cytosol involves two separate cleavage events. *Mol Cell Biol* 2004;24:454–464. [PubMed: 14673177]
119. Baccarini M, Dello Sbarba P, Buscher D, Bartocci A, Stanley ER. IFN-gamma/lipopolysaccharide activation of macrophages is associated with protein kinase C-dependent down-modulation of the colony-stimulating factor-1 receptor. *J Immunol* 1992;149:2656–2661. [PubMed: 1401905]
120. Rovida E, Paccagnini A, Del Rosso M, Peschon J, Dello Sbarba P. TNF-alpha-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation. *J Immunol* 2001;166:1583–1589. [PubMed: 11160199]
121. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines EW. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXCL12 chemokine ligand 16. *J Immunol* 2004;172:3678–3685. [PubMed: 15004171]
122. Schulte A, Schulz B, Andrzejewski MG, Hundhausen C, Mletzko S, Achilles J, Reiss K, Paliga K, Weber C, John SR, Ludwig A. Sequential processing of the transmembrane chemokines CX3CL1 and CXCL16 by alpha- and gamma-secretases. *Biochem Biophys Res Commun* 2007;358:233–240. [PubMed: 17467666]
123. Garton KJ, Gough PJ, Raines EW. Emerging roles for ectodomain shedding in the regulation of inflammatory responses. *J Leukoc Biol* 2006;79:1105–1116. [PubMed: 16565325]
124. Garton KJ, Gough PJ, Blobel CP, Murphy G, Greaves DR, Dempsey PJ, Raines EW. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). *J Biol Chem* 2001;276:37993–38001. [PubMed: 11495925]
125. Hundhausen C, Misztela D, Berkhout TA, Broadway N, Saftig P, Reiss K, Hartmann D, Fahrenholz F, Postina R, Matthews V, Kallen KJ, Rose-John S, Ludwig A. The disintegrin-like

- metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. *Blood* 2003;102:1186–1195. [PubMed: 12714508]
126. Taniguchi Y, Kim SH, Sisodia SS. Presenilin-dependent “gamma-secretase” processing of deleted in colorectal cancer (DCC). *J Biol Chem* 2003;278:30425–30428. [PubMed: 12840034]
 127. Bland CE, Kimberly P, Rand MD. Notch-induced proteolysis and nuclear localization of the Delta ligand. *J Biol Chem* 2003;278:13607–13610. [PubMed: 12591935]
 128. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, Zolkiewska A. Proteolytic processing of delta-like 1 by ADAM proteases. *J Biol Chem* 2007;282:436–444. [PubMed: 17107962]
 129. Six E, Ndiaye D, Laabi Y, Brou C, Gupta-Rossi N, Israel A, Logeat F. The Notch ligand Delta1 is sequentially cleaved by an ADAM protease and gamma-secretase. *Proc Natl Acad Sci U S A* 2003;100:7638–7643. [PubMed: 12794186]
 130. Ikeuchi T, Sisodia SS. The Notch ligands, Delta1 and Jagged2, are substrates for presenilin-dependent “gamma-secretase” cleavage. *J Biol Chem* 2003;278:7751–7754. [PubMed: 12551931]
 131. LaVoie MJ, Selkoe DJ. The Notch ligands, Jagged and Delta, are sequentially processed by alpha-secretase and presenilin/gamma-secretase and release signaling fragments. *J Biol Chem* 2003;278:34427–34437. [PubMed: 12826675]
 132. Marambaud P, Shioi J, Serban G, Georgakopoulos A, Sarner S, Nagy V, Baki L, Wen P, Efthimiopoulos S, Shao Z, Wisniewski T, Robakis NK. A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. *EMBO J* 2002;21:1948–1956. [PubMed: 11953314]
 133. Maretzky T, Reiss K, Ludwig A, Buchholz J, Scholz F, Proksch E, de Strooper B, Hartmann D, Saftig P. ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. *Proc Natl Acad Sci U S A* 2005;102:9182–9187. [PubMed: 15958533]
 134. Ito K, Okamoto I, Araki N, Kawano Y, Nakao M, Fujiyama S, Tomita K, Mimori T, Saya H. Calcium influx triggers the sequential proteolysis of extracellular and cytoplasmic domains of E-cadherin, leading to loss of beta-catenin from cell-cell contacts. *Oncogene* 1999;18:7080–7090. [PubMed: 10597309]
 135. Tomita T, Tanaka S, Morohashi Y, Iwatsubo T. Presenilin-dependent intramembrane cleavage of ephrin-B1. *Mol Neurodegener* 2006;1:2. [PubMed: 16930449]
 136. Georgakopoulos A, Litterst C, Ghersi E, Baki L, Xu C, Serban G, Robakis NK. Metalloproteinase/Presenilin1 processing of ephrinB regulates EphB-induced Src phosphorylation and signaling. *EMBO J* 2006;25:1242–1252. [PubMed: 16511561]
 137. Litterst C, Georgakopoulos A, Shioi J, Ghersi E, Wisniewski T, Wang R, Ludwig A, Robakis NK. Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. *J Biol Chem* 2007;282:16155–16163. [PubMed: 17428795]
 138. Ni CY, Murphy MP, Golde TE, Carpenter G. gamma-Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. *Science* 2001;294:2179–2181. [PubMed: 11679632]
 139. Vidal GA, Naresh A, Marrero L, Jones FE. Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities. *J Biol Chem* 2005;280:19777–19783. [PubMed: 15746097]
 140. Cheng QC, Tikhomirov O, Zhou W, Carpenter G. Ectodomain cleavage of ErbB-4: characterization of the cleavage site and m80 fragment. *J Biol Chem* 2003;278:38421–38427. [PubMed: 12869563]
 141. Zhou W, Carpenter G. Heregulin-dependent trafficking and cleavage of ErbB-4. *J Biol Chem* 2000;275:34737–34743. [PubMed: 10944525]
 142. Rio C, Buxbaum JD, Peschon JJ, Corfas G. Tumor necrosis factor-alpha-converting enzyme is required for cleavage of erbB4/HER4. *J Biol Chem* 2000;275:10379–10387. [PubMed: 10744726]
 143. Cowan JW, Wang X, Guan R, He K, Jiang J, Baumann G, Black RA, Wolfe MS, Frank SJ. Growth hormone receptor is a target for presenilin-dependent gamma-secretase cleavage. *J Biol Chem* 2005;280:19331–19342. [PubMed: 15743767]
 144. Zhang Y, Guan R, Jiang J, Kopchick JJ, Black RA, Baumann G, Frank SJ. Growth hormone (GH)-induced dimerization inhibits phorbol ester-stimulated GH receptor proteolysis. *J Biol Chem* 2001;276:24565–24573. [PubMed: 11309389]

145. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor- α converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. *Endocrinology* 2000;141:4342–4348. [PubMed: 11108241]
146. Carey BW, Kim DY, Kovacs DM. Presenilin/gamma-secretase and alpha-secretase-like peptidases cleave human MHC Class I proteins. *Biochem J* 2007;401:121–127. [PubMed: 17150042]
147. McElroy B, Powell JC, McCarthy JV. The insulin-like growth factor 1 (IGF-1) receptor is a substrate for gamma-secretase-mediated intramembrane proteolysis. *Biochem Biophys Res Commun* 2007;358:1136–1141. [PubMed: 17524361]
148. Saleh AZ, Fang AT, Arch AE, Neupane D, El Fiky A, Krolewski JJ. Regulated proteolysis of the IFN α 2 subunit of the interferon- α receptor. *Oncogene* 2004;23:7076–7086. [PubMed: 15286706]
149. Kuhn PH, Marjaux E, Imhof A, De Strooper B, Haass C, Lichtenthaler SF. Regulated intramembrane proteolysis of the interleukin-1 receptor II by alpha-, beta-, and gamma-secretase. *J Biol Chem* 2007;282:11982–11995. [PubMed: 17307738]
150. Kasuga K, Kaneko H, Nishizawa M, Onodera O, Ikeuchi T. Generation of intracellular domain of insulin receptor tyrosine kinase by gamma-secretase. *Biochem Biophys Res Commun* 2007;360:90–96. [PubMed: 17577576]
151. Niwa M, Sidrauski C, Kaufman RJ, Walter P. A role for presenilin-1 in nuclear accumulation of Ire1 fragments and induction of the mammalian unfolded protein response. *Cell* 1999;99:691–702. [PubMed: 10619423]
152. Maretzky T, Schulte M, Ludwig A, Rose-John S, Blobel C, Hartmann D, Altevogt P, Saftig P, Reiss K. L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. *Mol Cell Biol* 2005;25:9040–9053. [PubMed: 16199880]
153. May P, Reddy YK, Herz J. Proteolytic processing of low density lipoprotein receptor-related protein mediates regulated release of its intracellular domain. *J Biol Chem* 2002;277:18736–18743. [PubMed: 11907044]
154. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hsieh TT, Ranganathan S, Battey FD, Liu CX, Bacsikai BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. *J Biol Chem* 2005;280:17777–17785. [PubMed: 15749709]
155. Rozanov DV, Hahn-Dantona E, Strickland DK, Strongin AY. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. *J Biol Chem* 2004;279:4260–4268. [PubMed: 14645246]
156. Liu CX, Ranganathan S, Robinson S, Strickland DK. gamma-Secretase-mediated release of the low density lipoprotein receptor-related protein 1B intracellular domain suppresses anchorage-independent growth of neuroglioma cells. *J Biol Chem* 2007;282:7504–7511. [PubMed: 17227771]
157. Zou Z, Chung B, Nguyen T, Mentone S, Thomson B, Biemesderfer D. Linking receptor-mediated endocytosis and cell signaling: evidence for regulated intramembrane proteolysis of megalin in proximal tubule. *J Biol Chem* 2004;279:34302–34310. [PubMed: 15180987]
158. Mi K, Johnson GV. Regulated proteolytic processing of LRP6 results in release of its intracellular domain. *J Neurochem* 2007;101:517–529. [PubMed: 17326769]
159. Uemura K, Kihara T, Kuzuya A, Okawa K, Nishimoto T, Ninomiya H, Sugimoto H, Kinoshita A, Shimohama S. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. *Neurosci Lett* 2006;402:278–283. [PubMed: 16687212]
160. Reiss K, Maretzky T, Ludwig A, Tousseyn T, de Strooper B, Hartmann D, Saftig P. ADAM10 cleavage of N-cadherin and regulation of cell-cell adhesion and beta-catenin nuclear signalling. *EMBO J* 2005;24:742–752. [PubMed: 15692570]
161. Kim DY, Ingano LA, Kovacs DM. Nectin-1 α , an immunoglobulin-like receptor involved in the formation of synapses, is a substrate for presenilin/gamma-secretase-like cleavage. *J Biol Chem* 2002;277:49976–49981. [PubMed: 12376527]

162. De Strooper B, Annaert W, Cupers P, Saftig P, Craessaerts K, Mumm JS, Schroeter EH, Schrijvers V, Wolfe MS, Ray WJ, Goate A, Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. *Nature* 1999;398:518–522. [PubMed: 10206645]
163. Okochi M, Steiner H, Fukumori A, Tanii H, Tomita T, Tanaka T, Iwatsubo T, Kudo T, Takeda M, Haass C. Presenilins mediate a dual intramembranous gamma-secretase cleavage of Notch-1. *EMBO J* 2002;21:5408–5416. [PubMed: 12374741]
164. Mumm JS, Schroeter EH, Saxena MT, Griesemer A, Tian X, Pan DJ, Ray WJ, Kopan R. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. *Mol Cell* 2000;5:197–206. [PubMed: 10882062]
165. Vooijs M, Schroeter EH, Pan Y, Blandford M, Kopan R. Ectodomain shedding and intramembrane cleavage of mammalian Notch proteins is not regulated through oligomerization. *J Biol Chem* 2004;279:50864–50873. [PubMed: 15448134]
166. Shimizu K, Chiba S, Hosoya N, Kumano K, Saito T, Kurokawa M, Kanda Y, Hamada Y, Hirai H. Binding of Delta1, Jagged1, and Jagged2 to Notch2 rapidly induces cleavage, nuclear translocation, and hyperphosphorylation of Notch2. *Mol Cell Biol* 2000;20:6913–6922. [PubMed: 10958687]
167. Saxena MT, Schroeter EH, Mumm JS, Kopan R. Murine notch homologs (N1-4) undergo presenilin-dependent proteolysis. *J Biol Chem* 2001;276:40268–40273. [PubMed: 11518718]
168. Gowrishankar K, Zeidler MG, Vincenz C. Release of a membrane-bound death domain by gamma-secretase processing of the p75NTR homolog NRADD. *J Cell Sci* 2004;117:4099–4111. [PubMed: 15280425]
169. Zampieri N, Xu CF, Neubert TA, Chao MV. Cleavage of p75 neurotrophin receptor by alpha-secretase and gamma-secretase requires specific receptor domains. *J Biol Chem* 2005;280:14563–14571. [PubMed: 15701642]
170. Kanning KC, Hudson M, Amieux PS, Wiley JC, Bothwell M, Schecterson LC. Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. *J Neurosci* 2003;23:5425–5436. [PubMed: 12843241]
171. Frade JM. Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. *J Neurosci* 2005;25:1407–1411. [PubMed: 15703394]
172. Weskamp G, Schlondorff J, Lum L, Becherer JD, Kim TW, Saftig P, Hartmann D, Murphy G, Blobel CP. Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). *J Biol Chem* 2004;279:4241–4249. [PubMed: 14638693]
173. Urrea S, Escudero CA, Ramos P, Lisbona F, Allende E, Covarrubias P, Parraguez JI, Zampieri N, Chao MV, Annaert W, Bronfman FC. TrkA receptor activation by nerve growth factor induces shedding of the p75 neurotrophin receptor followed by endosomal gamma-secretase-mediated release of the p75 intracellular domain. *J Biol Chem* 2007;282:7606–7615. [PubMed: 17215246]
174. Kaimori JY, Nagasawa Y, Menezes LF, Garcia-Gonzalez MA, Deng J, Imai E, Onuchic LF, Guay-Woodford LM, Germino GG. Polyductin undergoes notch-like processing and regulated release from primary cilia. *Hum Mol Genet* 2007;16:942–956. [PubMed: 17470460]
175. Hiesberger T, Gourley E, Erickson A, Koulen P, Ward CJ, Masyuk TV, Larusso NF, Harris PC, Igarashi P. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca²⁺ and activation of protein kinase C. *J Biol Chem* 2006;281:34357–34364. [PubMed: 16956880]
176. Bonn S, Seeburg PH, Schwarz MK. Combinatorial expression of alpha- and gamma-protocadherins alters their presenilin-dependent processing. *Mol Cell Biol* 2007;27:4121–4132. [PubMed: 17403907]
177. Haas IG, Frank M, Veron N, Kemler R. Presenilin-dependent processing and nuclear function of gamma-protocadherins. *J Biol Chem* 2005;280:9313–9319. [PubMed: 15611067]
178. Anders L, Mertins P, Lammich S, Murgia M, Hartmann D, Saftig P, Haass C, Ullrich A. Furin-, ADAM 10-, and gamma-secretase-mediated cleavage of a receptor tyrosine phosphatase and regulation of beta-catenin's transcriptional activity. *Mol Cell Biol* 2006;26:3917–3934. [PubMed: 16648485]
179. Haapasalo A, Kim DY, Carey BW, Turunen MK, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase-mediated cleavage regulates association of leukocyte-common antigen-related (LAR)

- receptor tyrosine phosphatase with beta-catenin. *J Biol Chem* 2007;282:9063–9072. [PubMed: 17259169]
180. Aicher B, Lerch MM, Muller T, Schilling J, Ullrich A. Cellular redistribution of protein tyrosine phosphatases LAR and PTPsigma by inducible proteolytic processing. *J Cell Biol* 1997;138:681–696. [PubMed: 9245795]
 181. Ruhe JE, Streit S, Hart S, Ullrich A. EGFR signaling leads to downregulation of PTP-LAR via TACE-mediated proteolytic processing. *Cell Signal* 2006;18:1515–1527. [PubMed: 16478662]
 182. Nyborg AC, Ladd TB, Zwizinski CW, Lah JJ, Golde TE. Sortilin, SorCS1b, and SorLA Vps10p sorting receptors, are novel gamma-secretase substrates. *Mol Neurodegener* 2006;1:3. [PubMed: 16930450]
 183. Hermey G, Sjogaard SS, Petersen CM, Nykjaer A, Gliemann J. Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. *Biochem J* 2006;395:285–293. [PubMed: 16393139]
 184. Bohm C, Seibel NM, Henkel B, Steiner H, Haass C, Hampe W. SorLA signaling by regulated intramembrane proteolysis. *J Biol Chem* 2006;281:14547–14553. [PubMed: 16531402]
 185. Hampe W, Riedel IB, Lintzel J, Bader CO, Franke I, Schaller HC. Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. *J Cell Sci* 2000;113 (Pt 24):4475–4485. [PubMed: 11082041]
 186. Schulz JG, Annaert W, Vandekerckhove J, Zimmermann P, De Strooper B, David G. Syndecan 3 intramembrane proteolysis is presenilin/gamma-secretase-dependent and modulates cytosolic signaling. *J Biol Chem* 2003;278:48651–48657. [PubMed: 14504279]
 187. Wang R, Tang P, Wang P, Boissy RE, Zheng H. Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation. *Proc Natl Acad Sci U S A* 2006;103:353–358. [PubMed: 16384915]
 188. Cai J, Jiang WG, Grant MB, Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. *J Biol Chem* 2006;281:3604–3613. [PubMed: 16339148]
 189. Kim DY, Ingano LA, Carey BW, Pettingell WH, Kovacs DM. Presenilin/gamma-secretase-mediated cleavage of the voltage-gated sodium channel beta2-subunit regulates cell adhesion and migration. *J Biol Chem* 2005;280:23251–23261. [PubMed: 15833746]
 190. Wong HK, Sakurai T, Oyama F, Kaneko K, Wada K, Miyazaki H, Kurosawa M, De Strooper B, Saftig P, Nukina N. beta Subunits of voltage-gated sodium channels are novel substrates of beta-site amyloid precursor protein-cleaving enzyme (BACE1) and gamma-secretase. *J Biol Chem* 2005;280:23009–23017. [PubMed: 15824102]
 191. Sugahara KN, Murai T, Nishinakamura H, Kawashima H, Saya H, Miyasaka M. Hyaluronan oligosaccharides induce CD44 cleavage and promote cell migration in CD44-expressing tumor cells. *J Biol Chem* 2003;278:32259–32265. [PubMed: 12801931]
 192. Murai T, Miyazaki Y, Nishinakamura H, Sugahara KN, Miyauchi T, Sako Y, Yanagida T, Miyasaka M. Engagement of CD44 promotes Rac activation and CD44 cleavage during tumor cell migration. *J Biol Chem* 2004;279:4541–4550. [PubMed: 14623895]
 193. Scheuermann S, Hambsch B, Hesse L, Stumm J, Schmidt C, Beher D, Bayer TA, Beyreuther K, Multhaup G. Homodimerization of amyloid precursor protein and its implication in the amyloidogenic pathway of Alzheimer's disease. *J Biol Chem* 2001;276:33923–33929. [PubMed: 11438549]
 194. Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Lower A, Langer A, Merdes G, Paro R, Masters CL, Muller U, Kins S, Beyreuther K. Homo- and heterodimerization of APP family members promotes intercellular adhesion. *EMBO J* 2005;24:3624–3634. [PubMed: 16193067]
 195. Asundi VK, Carey DJ. Self-association of N-syndecan (syndecan-3) core protein is mediated by a novel structural motif in the transmembrane domain and ectodomain flanking region. *J Biol Chem* 1995;270:26404–26410. [PubMed: 7592855]
 196. Yi JY, Han I, Oh ES. Transmembrane domain-dependent functional oligomerization of syndecans. *ScientificWorldJournal* 2006;6:457–459. [PubMed: 16604258]
 197. Koch AW, Bozic D, Pertz O, Engel J. Homophilic adhesion by cadherins. *Curr Opin Struct Biol* 1999;9:275–281. [PubMed: 10322209]

198. Suzuki ST. Recent progress in protocadherin research. *Exp Cell Res* 2000;261:13–18. [PubMed: 11082270]
199. Mizoguchi A, Nakanishi H, Kimura K, Matsubara K, Ozaki-Kuroda K, Katata T, Honda T, Kiyohara Y, Heo K, Higashi M, Tsutsumi T, Sonoda S, Ide C, Takai Y. Nectin: an adhesion molecule involved in formation of synapses. *J Cell Biol* 2002;156:555–565. [PubMed: 11827984]
200. Holm J, Appel F, Schachner M. Several extracellular domains of the neural cell adhesion molecule L1 are involved in homophilic interactions. *J Neurosci Res* 1995;42:9–20. [PubMed: 8531230]
201. Chung HM, Struhl G. Nicastrin is required for Presenilin-mediated transmembrane cleavage in *Drosophila*. *Nat Cell Biol* 2001;3:1129–1132. [PubMed: 11781576]
202. Esler WP, Kimberly WT, Ostaszewski BL, Ye W, Diehl TS, Selkoe DJ, Wolfe MS. Activity-dependent isolation of the presenilin- gamma -secretase complex reveals nicastrin and a gamma substrate. *Proc Natl Acad Sci U S A* 2002;99:2720–2725. [PubMed: 11867728]
203. Beher D, Fricker M, Nadin A, Clarke EE, Wrigley JD, Li YM, Culvenor JG, Masters CL, Harrison T, Shearman MS. In vitro characterization of the presenilin-dependent gamma-secretase complex using a novel affinity ligand. *Biochemistry* 2003;42:8133–8142. [PubMed: 12846562]
204. Tian G, Sobotka-Briner CD, Zysk J, Liu X, Birr C, Sylvester MA, Edwards PD, Scott CD, Greenberg BD. Linear non-competitive inhibition of solubilized human gamma-secretase by pepstatin A methylester, L685458, sulfonamides, and benzodiazepines. *J Biol Chem* 2002;277:31499–31505. [PubMed: 12072428]
205. Tian G, Ghanekar SV, Aharony D, Shenvi AB, Jacobs RT, Liu X, Greenberg BD. The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors. *J Biol Chem* 2003;278:28968–28975. [PubMed: 12719412]
206. Berezovska O, Ramdya P, Skoch J, Wolfe MS, Bacskai BJ, Hyman BT. Amyloid precursor protein associates with a nicastrin-dependent docking site on the presenilin 1-gamma-secretase complex in cells demonstrated by fluorescence lifetime imaging. *J Neurosci* 2003;23:4560–4566. [PubMed: 12805296]
207. Kornilova AY, Bihel F, Das C, Wolfe MS. The initial substrate-binding site of gamma-secretase is located on presenilin near the active site. *Proc Natl Acad Sci U S A* 2005;102:3230–3235. [PubMed: 15722417]
208. Yamasaki A, Eimer S, Okochi M, Smialowska A, Kaether C, Baumeister R, Haass C, Steiner H. The GxGD motif of presenilin contributes to catalytic function and substrate identification of gamma-secretase. *J Neurosci* 2006;26:3821–3828. [PubMed: 16597736]
209. Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc Natl Acad Sci U S A* 1998;95:6460–6464. [PubMed: 9600988]
210. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. *Neurobiol Dis* 2000;7:321–331. [PubMed: 10964604]
211. Frears ER, Stephens DJ, Walters CE, Davies H, Austen BM. The role of cholesterol in the biosynthesis of beta-amyloid. *Neuroreport* 1999;10:1699–1705. [PubMed: 10501560]
212. Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta —amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. *Proc Natl Acad Sci U S A* 2001;98:5856–5861. [PubMed: 11296263]
213. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. *Lancet* 2000;356:1627–1631. [PubMed: 11089820]
214. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch Neurol* 2000;57:1439–1443. [PubMed: 11030795]
215. Riddell DR, Christie G, Hussain I, Dingwall C. Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. *Curr Biol* 2001;11:1288–1293. [PubMed: 11525745]
216. Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. *Neurobiol Dis* 2002;9:11–23. [PubMed: 11848681]

217. Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, Wong PC, Xu H, Thinakaran G. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. *J Biol Chem* 2004;279:44945–44954. [PubMed: 15322084]
218. Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, Noguchi N, Tomita T, Iwatsubo T, Hamakubo T, Kodama T. Association of active gamma-secretase complex with lipid rafts. *J Lipid Res* 2005;46:904–912. [PubMed: 15716592]
219. Cheng H, Vetrivel KS, Gong P, Meckler X, Parent A, Thinakaran G. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease--targeting APP processing in lipid rafts. *Nat Clin Pract Neurol* 2007;3:374–382. [PubMed: 17611486]
220. Höglund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1-40), beta-amyloid(1-42), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. *Arch Neurol* 2004;61:333–337. [PubMed: 15023808]
221. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins reduce amyloid-beta production through inhibition of protein isoprenylation. *J Biol Chem* 2007;282:26832–26844. [PubMed: 17646164]
222. Brown DA, London E. Functions of lipid rafts in biological membranes. *Annu Rev Cell Dev Biol* 1998;14:111–136. [PubMed: 9891780]
223. Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. *Mol Membr Biol* 2006;23:111–122. [PubMed: 16611586]
224. Reid PC, Urano Y, Kodama T, Hamakubo T. Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins. *J Cell Mol Med* 2007;11:383–392. [PubMed: 17635634]
225. Chen TY, Liu PH, Ruan CT, Chiu L, Kung FL. The intracellular domain of amyloid precursor protein interacts with flotillin-1, a lipid raft protein. *Biochem Biophys Res Commun* 2006;342:266–272. [PubMed: 16480949]
226. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. *J Biol Chem* 2003;278:19777–19783. [PubMed: 12649271]
227. Sawamura N, Ko M, Yu W, Zou K, Hanada K, Suzuki T, Gong JS, Yanagisawa K, Michikawa M. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. *J Biol Chem* 2004;279:11984–11991. [PubMed: 14715666]
228. Tamboli IY, Prager K, Barth E, Heneka M, Sandhoff K, Walter J. Inhibition of glycosphingolipid biosynthesis reduces secretion of the beta-amyloid precursor protein and amyloid beta-peptide. *J Biol Chem* 2005;280:28110–28117. [PubMed: 15923191]
229. Kalvodova L, Kahya N, Schwille P, Ehehalt R, Verkade P, Drechsel D, Simons K. Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro. *J Biol Chem* 2005;280:36815–36823. [PubMed: 16115865]
230. Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Li B, Paul SM, Sambamurti K. Geranylgeranyl pyrophosphate stimulates {gamma}-secretase to increase the generation of A{beta} and APP-CTF{gamma}. *FASEB J*. 2007
231. Ehehalt R, Keller P, Haass C, Thiele C, Simons K. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. *J Cell Biol* 2003;160:113–123. [PubMed: 12515826]
232. Cordy JM, Hussain I, Dingwall C, Hooper NM, Turner AJ. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc Natl Acad Sci U S A* 2003;100:11735–11740. [PubMed: 14504402]
233. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. *Proc Natl Acad Sci U S A* 2001;98:5815–5820. [PubMed: 11309494]
234. Vetrivel KS, Cheng H, Kim SH, Chen Y, Barnes NY, Parent AT, Sisodia SS, Thinakaran G. Spatial segregation of gamma-secretase and substrates in distinct membrane domains. *J Biol Chem* 2005;280:25892–25900. [PubMed: 15886206]
235. Gil C, Cubi R, Aguilera J. Shedding of the p75NTR neurotrophin receptor is modulated by lipid rafts. *FEBS Lett* 2007;581:1851–1858. [PubMed: 17433308]

236. Cherukuri A, Dykstra M, Pierce SK. Floating the raft hypothesis: lipid rafts play a role in immune cell activation. *Immunity* 2001;14:657–660. [PubMed: 11420035]
237. Montixi C, Langlet C, Bernard AM, Thimonier J, Dubois C, Wurzel MA, Chauvin JP, Pierres M, He HT. Engagement of T cell receptor triggers its recruitment to low-density detergent-insoluble membrane domains. *EMBO J* 1998;17:5334–5348. [PubMed: 9736612]
238. Field KA, Holowka D, Baird B. Compartmentalized activation of the high affinity immunoglobulin E receptor within membrane domains. *J Biol Chem* 1997;272:4276–4280. [PubMed: 9020144]
239. Legler DF, Micheau O, Doucey MA, Tschoep J, Bron C. Recruitment of TNF receptor 1 to lipid rafts is essential for TNF α -mediated NF- κ B activation. *Immunity* 2003;18:655–664. [PubMed: 12753742]
240. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. *Cell* 2001;106:403–411. [PubMed: 11525727]
241. Riddell DR, Sun XM, Stannard AK, Soutar AK, Owen JS. Localization of apolipoprotein E receptor 2 to caveolae in the plasma membrane. *J Lipid Res* 2001;42:998–1002. [PubMed: 11369809]
242. Thankamony SP, Knudson W. Acylation of CD44 and its association with lipid rafts are required for receptor and hyaluronan endocytosis. *J Biol Chem* 2006;281:34601–34609. [PubMed: 16945930]
243. Herincs Z, Corset V, Cahuzac N, Furne C, Castellani V, Hueber AO, Mehlen P. DCC association with lipid rafts is required for netrin-1-mediated axon guidance. *J Cell Sci* 2005;118:1687–1692. [PubMed: 15811950]
244. Huo H, Guo X, Hong S, Jiang M, Liu X, Liao K. Lipid rafts/caveolae are essential for insulin-like growth factor-1 receptor signaling during 3T3-L1 preadipocyte differentiation induction. *J Biol Chem* 2003;278:11561–11569. [PubMed: 12538586]
245. Wu L, Gonias SL. The low-density lipoprotein receptor-related protein-1 associates transiently with lipid rafts. *J Cell Biochem* 2005;96:1021–1033. [PubMed: 16149055]
246. Causseret M, Taulet N, Comunale F, Favard C, Gauthier-Rouviere C. N-cadherin association with lipid rafts regulates its dynamic assembly at cell-cell junctions in C2C12 myoblasts. *Mol Biol Cell* 2005;16:2168–2180. [PubMed: 15716354]
247. Bruckner K, Pablo-Labrador J, Scheiffele P, Herb A, Seeburg PH, Klein R. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. *Neuron* 1999;22:511–524. [PubMed: 10197531]
248. Ma L, Huang YZ, Pitcher GM, Valtschanoff JG, Ma YH, Feng LY, Lu B, Xiong WC, Salter MW, Weinberg RJ, Mei L. Ligand-dependent recruitment of the ErbB4 signaling complex into neuronal lipid rafts. *J Neurosci* 2003;23:3164–3175. [PubMed: 12716924]
249. Yang N, Huang Y, Jiang J, Frank SJ. Caveolar and lipid raft localization of the growth hormone receptor and its signaling elements: impact on growth hormone signaling. *J Biol Chem* 2004;279:20898–20905. [PubMed: 15010456]
250. Lebedeva T, Anikeeva N, Kalams SA, Walker BD, Gaidarov I, Keen JH, Sykulev Y. Major histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of target cells: implications for antigen presentation to cytotoxic T lymphocytes. *Immunology* 2004;113:460–471. [PubMed: 15554924]
251. Yamamoto H, Komekado H, Kikuchi A. Caveolin is necessary for Wnt-3a-dependent internalization of LRP6 and accumulation of beta-catenin. *Dev Cell* 2006;11:213–223. [PubMed: 16890161]
252. Higuchi H, Yamashita T, Yoshikawa H, Tohyama M. PKA phosphorylates the p75 receptor and regulates its localization to lipid rafts. *EMBO J* 2003;22:1790–1800. [PubMed: 12682012]
253. Cam JA, Zerbiniatti CV, Li Y, Bu G. Rapid endocytosis of the low density lipoprotein receptor-related protein modulates cell surface distribution and processing of the beta-amyloid precursor protein. *J Biol Chem* 2005;280:15464–15470. [PubMed: 15705569]
254. Pietrzik CU, Busse T, Merriam DE, Weggen S, Koo EH. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. *EMBO J* 2002;21:5691–5700. [PubMed: 12411487]
255. Yoon IS, Pietrzik CU, Kang DE, Koo EH. Sequences from the low density lipoprotein receptor-related protein (LRP) cytoplasmic domain enhance amyloid beta protein production via the beta-

- secretase pathway without altering amyloid precursor protein/LRP nuclear signaling. *J Biol Chem* 2005;280:20140–20147. [PubMed: 15772078]
256. Yoon IS, Chen E, Busse T, Repetto E, Lakshmana MK, Koo EH, Kang DE. Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. *FASEB J* 2007;21:2742–2752. [PubMed: 17463224]
 257. von Arnim CA, Kinoshita A, Peltan ID, Tangredi MM, Herl L, Lee BM, Spoelgen R, Hsieh TT, Ranganathan S, Battey FD, Liu CX, Bacskaï BJ, Sever S, Irizarry MC, Strickland DK, Hyman BT. The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. *J Biol Chem* 2005;280:17777–17785. [PubMed: 15749709]
 258. Cam JA, Zerbinatti CV, Knisely JM, Hecimovic S, Li Y, Bu G. The low density lipoprotein receptor-related protein 1B retains beta-amyloid precursor protein at the cell surface and reduces amyloid-beta peptide production. *J Biol Chem* 2004;279:29639–29646. [PubMed: 15126508]
 259. ShahSYuGsorLA: sorting out APP. *Mol Interv* 2006;6:7476, 58. [PubMed: 16565469]
 260. Offe K, Dodson SE, Shoemaker JT, Fritz JJ, Gearing M, Levey AI, Lah JJ. The lipoprotein receptor LR11 regulates amyloid beta production and amyloid precursor protein traffic in endosomal compartments. *J Neurosci* 2006;26:1596–1603. [PubMed: 16452683]
 261. Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CA, Breiderhoff T, Jansen P, Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE. Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. *Proc Natl Acad Sci U S A* 2005;102:13461–13466. [PubMed: 16174740]
 262. Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, Irizarry MC, Andersen OM, Willnow TE, Hyman BT. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. *J Neurosci* 2006;26:418–428. [PubMed: 16407538]
 263. Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinsty WJ, Parker MW, Masters CL, Hyman BT, Cappai R, Willnow TE. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. *Biochemistry* 2006;45:2618–2628. [PubMed: 16489755]
 264. Fuentealba RA, Barria MI, Lee J, Cam J, Araya C, Escudero CA, Inestrosa NC, Bronfman FC, Bu G, Marzolo MP. ApoER2 expression increases Abeta production while decreasing Amyloid Precursor Protein (APP) endocytosis: Possible role in the partitioning of APP into lipid rafts and in the regulation of gamma-secretase activity. *Mol Neurodegener* 2007;2:14. [PubMed: 17620134]
 265. Miller CC, McLoughlin DM, Lau KF, Tennant ME, Rogelj B. The X11 proteins, Abeta production and Alzheimer's disease. *Trends Neurosci* 2006;29:280–285. [PubMed: 16545469]
 266. Xie Z, Romano DM, Tanzi RE. RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. *J Biol Chem* 2005;280:15413–15421. [PubMed: 15699037]
 267. Araki Y, Tomita S, Yamaguchi H, Miyagi N, Sumioka A, Kirino Y, Suzuki T. Novel cadherin-related membrane proteins, Alcadeins, enhance the X11-like protein-mediated stabilization of amyloid beta-protein precursor metabolism. *J Biol Chem* 2003;278:49448–49458. [PubMed: 12972431]
 268. Ho CS, Marinescu V, Steinhilb ML, Gaut JR, Turner RS, Stuenkel EL. Synergistic effects of Munc18a and X11 proteins on amyloid precursor protein metabolism. *J Biol Chem* 2002;277:27021–27028. [PubMed: 12016213]
 269. Borg JP, Yang Y, De Taddeo-Borg M, Margolis B, Turner RS. The X11alpha protein slows cellular amyloid precursor protein processing and reduces Abeta40 and Abeta42 secretion. *J Biol Chem* 1998;273:14761–14766. [PubMed: 9614075]
 270. Sastre M, Turner RS, Levy E. X11 interaction with beta-amyloid precursor protein modulates its cellular stabilization and reduces amyloid beta-protein secretion. *J Biol Chem* 1998;273:22351–22357. [PubMed: 9712855]
 271. Lee JH, Lau KF, Perkinton MS, Standen CL, Shemilt SJ, Mercken L, Cooper JD, McLoughlin DM, Miller CC. The neuronal adaptor protein X11alpha reduces Abeta levels in the brains of Alzheimer's APPswe Tg2576 transgenic mice. *J Biol Chem* 2003;278:47025–47029. [PubMed: 12970358]

272. Lee JH, Lau KF, Perkinton MS, Standen CL, Rogelj B, Falinska A, McLoughlin DM, Miller CC. The neuronal adaptor protein X11beta reduces amyloid beta-protein levels and amyloid plaque formation in the brains of transgenic mice. *J Biol Chem* 2004;279:49099–49104. [PubMed: 15347685]
273. Shrivastava-Ranjan P, Faundez V, Fang G, Rees H, Lah JJ, Levey AI, Kahn RA. Mint3/X11 {gamma} Is an Arf-dependent Adaptor that Regulates the Traffic of the Alzheimer's Precursor Protein from the TGN. *Mol Biol Cell*. 2007
274. Fiore F, Zambrano N, Minopoli G, Donini V, Duilio A, Russo T. The regions of the Fe65 protein homologous to the phosphotyrosine interaction/phosphotyrosine binding domain of Shc bind the intracellular domain of the Alzheimer's amyloid precursor protein. *J Biol Chem* 1995;270:30853–30856. [PubMed: 8537337]
275. Russo T, Faraonio R, Minopoli G, De Candi P, De Renzis S, Zambrano N. Fe65 and the protein network centered around the cytosolic domain of the Alzheimer's beta-amyloid precursor protein. *FEBS Lett* 1998;434:1–7. [PubMed: 9738440]
276. Sabo SL, Lanier LM, Ikin AF, Khorkova O, Sahasrabudhe S, Greengard P, Buxbaum JD. Regulation of beta-amyloid secretion by FE65, an amyloid protein precursor-binding protein. *J Biol Chem* 1999;274:7952–7957. [PubMed: 10075692]
277. Chang Y, Tesco G, Jeong WJ, Lindsley L, Eckman EA, Eckman CB, Tanzi RE, Guenette SY. Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. *J Biol Chem* 2003;278:51100–51107. [PubMed: 14527950]
278. Tanahashi H, Tabira T. Characterization of an amyloid precursor protein-binding protein Fe65L2 and its novel isoforms lacking phosphotyrosine-interaction domains. *Biochem J* 2002;367:687–695. [PubMed: 12153398]
279. Trommsdorff M, Borg JP, Margolis B, Herz J. Interaction of cytosolic adaptor proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein. *J Biol Chem* 1998;273:33556–33560. [PubMed: 9837937]
280. Kinoshita A, Whelan CM, Smith CJ, Mikhailenko I, Rebeck GW, Strickland DK, Hyman BT. Demonstration by fluorescence resonance energy transfer of two sites of interaction between the low-density lipoprotein receptor-related protein and the amyloid precursor protein: role of the intracellular adapter protein Fe65. *J Neurosci* 2001;21:8354–8361. [PubMed: 11606623]
281. Pietrzik CU, Yoon IS, Jaeger S, Busse T, Weggen S, Koo EH. FE65 constitutes the functional link between the low-density lipoprotein receptor-related protein and the amyloid precursor protein. *J Neurosci* 2004;24:4259–4265. [PubMed: 15115822]
282. Hoe HS, Magill LA, Guenette S, Fu Z, Vicini S, Rebeck GW. FE65 interaction with the ApoE receptor ApoE2. *J Biol Chem* 2006;281:24521–24530. [PubMed: 16638748]
283. Guenette SY, Chang Y, Hyman BT, Tanzi RE, Rebeck GW. Low-density lipoprotein receptor-related protein levels and endocytic function are reduced by overexpression of the FE65 adaptor protein, FE65L1. *J Neurochem* 2002;82:755–762. [PubMed: 12358780]
284. Howell BW, Lanier LM, Frank R, Gertler FB, Cooper JA. The disabled 1 phosphotyrosine-binding domain binds to the internalization signals of transmembrane glycoproteins and to phospholipids. *Mol Cell Biol* 1999;19:5179–5188. [PubMed: 10373567]
285. Homayouni R, Rice DS, Sheldon M, Curran T. Disabled-1 binds to the cytoplasmic domain of amyloid precursor-like protein 1. *J Neurosci* 1999;19:7507–7515. [PubMed: 10460257]
286. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. *Cell* 1999;97:689–701. [PubMed: 10380922]
287. Hoe HS, Tran TS, Matsuoka Y, Howell BW, Rebeck GW. DAB1 and Reelin effects on amyloid precursor protein and ApoE receptor 2 trafficking and processing. *J Biol Chem* 2006;281:35176–35185. [PubMed: 16951405]
288. Parisiadou L, Efthimiopoulos S. Expression of mDab1 promotes the stability and processing of amyloid precursor protein and this effect is counteracted by X11alpha. *Neurobiol Aging* 2007;28:377–388. [PubMed: 16458391]

289. Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D'Adamio L. Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP). *J Biol Chem* 2002;277:3767–3775. [PubMed: 11724784]
290. Pastorino L, Sun A, Lu P-J, Xiao ZZ, Balastik M, Finn G, Wulf G, Lim J, Li S-H, Li X, Xia W, Nicholson LK, Lu KP. The prolyl peptidase Pin1 regulates amyloid precursor protein processing and amyloid- β production. *Nature* 2006;440:528–534. [PubMed: 16554819]
291. Tarr PE, Roncarati R, Pelicci G, Pelicci PG, D'Adamio L. Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc. *J Biol Chem* 2002;277:16798–16804. [PubMed: 11877420]
292. Xie Z, Dong Y, Maeda U, Xia W, Tanzi RE. RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and A β generation. *J Biol Chem* 2007;282:4318–4325. [PubMed: 17170108]
293. Kuan YH, Gruebl T, Soba P, Eggert S, Nesic I, Back S, Kirsch J, Beyreuther K, Kins S. PAT1a modulates intracellular transport and processing of amyloid precursor protein (APP), APLP1, and APLP2. *J Biol Chem* 2006;281:40114–40123. [PubMed: 17050537]
294. Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D'Adamio L. The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. *J Biol Chem* 2005;280:28912–28916. [PubMed: 15983050]
295. Noviglio C, Vito P, Lopez P, Abdallah M, D'Adamio L. Autosomal recessive hypercholesterolemia protein interacts with and regulates the cell surface level of Alzheimer's amyloid beta precursor protein. *J Biol Chem* 2003;278:31843–31847. [PubMed: 12805363]
296. Fluhrer R, Grammer G, Israel L, Condron MM, Haffner C, Friedmann E, Bohland C, Imhof A, Martoglio B, Teplow DB, Haass C. A gamma-secretase-like intramembrane cleavage of TNF α by the GxGD aspartyl protease SPPL2b. *Nat Cell Biol* 2006;8:894–896. [PubMed: 16829951]
297. Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K, Evin G. A novel epsilon-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. *Biochemistry* 2002;41:2825–2835. [PubMed: 11851430]
298. Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L, Xu X. gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. *J Biol Chem* 2005;280:37689–37697. [PubMed: 16157587]
299. Zhao G, Cui MZ, Mao G, Dong Y, Tan J, Sun L, Xu X. gamma-Cleavage is dependent on zeta-cleavage during the proteolytic processing of amyloid precursor protein within its transmembrane domain. *J Biol Chem* 2005;280:37689–37697. [PubMed: 16157587]
300. Zhao G, Tan J, Mao G, Cui MZ, Xu X. The same gamma-secretase accounts for the multiple intramembrane cleavages of APP. *J Neurochem* 2007;100:1234–1246. [PubMed: 17241131]
301. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirokoshi N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, Ihara Y. Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. *J Neurosci* 2005;25:436–445. [PubMed: 15647487]
302. Chandu D, Huppert SS, Kopan R. Analysis of transmembrane domain mutants is consistent with sequential cleavage of Notch by gamma-secretase. *J Neurochem* 2006;96:228–235. [PubMed: 16300632]
303. Fortini ME. Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. *Nat Rev Mol Cell Biol* 2002;3:673–684. [PubMed: 12209127]
304. Kopan R, Ilagan MX. Gamma-secretase: proteasome of the membrane? *Nat Rev Mol Cell Biol* 2004;5:499–504. [PubMed: 15173829]
305. Evin G, Sernee MF, Masters CL. Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. *CNS Drugs* 2006;20:351–372. [PubMed: 16696577]
306. Vardy ER, Catto AJ, Hooper NM. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. *Trends Mol Med* 2005;11:464–472. [PubMed: 16153892]

307. Nakahara S, Saito T, Kondo N, Moriwaki K, Noda K, Ihara S, Takahashi M, Ide Y, Gu J, Inohara H, Katayama T, Tohyama M, Kubo T, Taniguchi N, Miyoshi E. A secreted type of beta1,6 N-acetylglucosaminyltransferase V (GnT-V), a novel angiogenesis inducer, is regulated by gamma-secretase. *FASEB J* 2006;20:2451–2459. [PubMed: 17142794]
308. Becker-Herman S, Arie G, Medvedovsky H, Kerem A, Shachar I. CD74 is a member of the regulated intramembrane proteolysis-processed protein family. *Mol Biol Cell* 2005;16:5061–5069. [PubMed: 16107560]
309. Meyer EL, Strutz N, Gahring LC, Rogers SW. Glutamate receptor subunit 3 is modified by site-specific limited proteolysis including cleavage by gamma-secretase. *J Biol Chem* 2003;278:23786–23796. [PubMed: 12700243]
310. Lichtenthaler SF, Wang R, Grimm H, Uljon SN, Masters CL, Beyreuther K. Mechanism of the cleavage specificity of Alzheimer's disease gamma-secretase identified by phenylalanine-scanning mutagenesis of the transmembrane domain of the amyloid precursor protein. *Proc Natl Acad Sci U S A* 1999;96:3053–3058. [PubMed: 10077635]
311. Tischer E, Cordell B. Beta-amyloid precursor protein. Location of transmembrane domain and specificity of gamma-secretase cleavage. *J Biol Chem* 1996;271:21914–21919. [PubMed: 8702994]
312. Lichtenthaler SF, Ida N, Multhaup G, Masters CL, Beyreuther K. Mutations in the transmembrane domain of APP altering gamma-secretase specificity. *Biochemistry* 1997;36:15396–15403. [PubMed: 9398269]
313. Zhang J, Ye W, Wang R, Wolfe MS, Greenberg BD, Selkoe DJ. Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. *J Biol Chem* 2002;277:15069–15075. [PubMed: 11839734]
314. Murphy MP, Hickman LJ, Eckman CB, Uljon SN, Wang R, Golde TE. gamma-Secretase, evidence for multiple proteolytic activities and influence of membrane positioning of substrate on generation of amyloid beta peptides of varying length. *J Biol Chem* 1999;274:11914–11923. [PubMed: 10207012]
315. Huppert SS, Le A, Schroeter EH, Mumm JS, Saxena MT, Milner LA, Kopan R. Embryonic lethality in mice homozygous for a processing-deficient allele of Notch1. *Nature* 2000;405:966–970. [PubMed: 10879540]
316. Jones DT. Protein secondary structure prediction based on position-specific scoring matrices. *J Mol Biol* 1999;292:195–202. [PubMed: 10493868]
317. Meiler J, Baker D. Coupled prediction of protein secondary and tertiary structure. *Proc Natl Acad Sci U S A* 2003;100:12105–12110. [PubMed: 14528006]
318. Meiler J, Müller M, Zeidler A, Schmäscke F. Generation and Evaluation of Dimension Reduced Amino Acid Parameter Representations by Artificial Neural Networks. *J Mol Model* 2001;7:360–369.
319. Huber O, Kemler R, Langosch D. Mutations affecting transmembrane segment interactions impair adhesiveness of E-cadherin. *J Cell Sci* 1999;112(Pt 23):4415–4423. [PubMed: 10564659]
320. Yonekura S, Ting CY, Neves G, Hung K, Hsu SN, Chiba A, Chess A, Lee CH. The variable transmembrane domain of Drosophila N-cadherin regulates adhesive activity. *Mol Cell Biol* 2006;26:6598–6608. [PubMed: 16914742]
321. Mendrola JM, Berger MB, King MC, Lemmon MA. The single transmembrane domains of ErbB receptors self-associate in cell membranes. *J Biol Chem* 2002;277:4704–4712. [PubMed: 11741943]
322. Munter LM, Voigt P, Harmeier A, Kaden D, Gottschalk KE, Weise C, Pipkorn R, Schaefer M, Langosch D, Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. *EMBO J* 2007;26:1702–1712. [PubMed: 17332749]
323. Chin CN, Sachs JN, Engelman DM. Transmembrane homodimerization of receptor-like protein tyrosine phosphatases. *FEBS Lett* 2005;579:3855–3858. [PubMed: 15978577]
324. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. *Annu Rev Biochem* 1993;62:453–481. [PubMed: 7688944]

325. Russ WP, Engelman DM. The GxxxG motif: a framework for transmembrane helix-helix association. *J Mol Biol* 2000;296:911–919. [PubMed: 10677291]
326. Senes A, Gerstein M, Engelman DM. Statistical analysis of amino acid patterns in transmembrane helices: the GxxxG motif occurs frequently and in association with beta-branched residues at neighboring positions. *J Mol Biol* 2000;296:921–936. [PubMed: 10677292]
327. Kleiger G, Grothe R, Mallick P, Eisenberg D. GXXXG and AXXXA: common alpha-helical interaction motifs in proteins, particularly in extremophiles. *Biochemistry* 2002;41:5990–5997. [PubMed: 11993993]

	Protease Class	Signature Catalytic Motifs	Initial Cleavage by Another Protease Required for IP?	Helix Destabilization at Site of Cleavage Facilitates IP?	Substrate Trafficking Controls Access to Protease?	Existence of a Consensus Sequence at Substrate Cleavage Site?	Multiple Cleavage Sites per Substrate?
S2P	Metalloprotease	HExxH	Yes	Yes	Yes	No	Unclear
Rhomboid	Serine protease	GxSG, H	No	Yes	Yes	No	Yes
SPP	Aspartyl protease	YD, LGxGD	Yes	Yes	Unclear	No	Yes
γ-secretase	Aspartyl protease	YD, LGxGD	Yes	Possibly*	Possibly	No	Yes

Figure 1. A summary of common themes among the I-CLiPs

Signature motifs are universally conserved among family members and are located in transmembrane regions of the protease. Residues in bold are directly involved in catalysis. With the exception of Rhomboid proteases, an initial ectodomain cleavage event facilitates subsequent intramembrane proteolysis (IP). The importance of helix destabilization is observed for virtually all I-CLiPs: flexibility of the transmembrane helix appears to be necessary for the protease to access the scissile region (*the potential importance of helix-destabilizing residues for γ -secretase-mediated IP is evaluated in this report). Trafficking of protease and substrate refers to whether these two entities are located in different organelles--a general control mechanism of IP that ensures that proteolysis occurs in a regulated fashion. In contrast to many other "classical" proteases, the cleavage sites of I-CLiPs are generally not delineated by canonical sequences. Lastly, multiple sites of cleavage have been identified for many of these proteases.

Figure 2. Proteolytic pathway of SREBP

SREBP (cyan) initially coexists in the ER with its escort protein, SCAP (orange) (bottom panel). The presence of sterols or oxysterols promotes an interaction with ER-resident anchor proteins known as Insigs (gray). Sterol depletion abrogates this interaction and the SREBP-SCAP complex translocates to the Golgi, whereupon SREBP is initially proteolyzed in its short luminal loop by S1P, a membrane-embedded serine protease. Following this cleavage, the transmembrane region of the SREBP N-terminal fragment is proteolyzed intramembranously by S2 protease (S2P) between a leucine and a cysteine, which results in liberation of the N-terminal domain. This domain is a transcription factor that translocates to the nucleus and up-regulates expression of genes involved in cholesterol biosynthesis. SCAP and Insigs are polytopic membrane proteins (not shown).

Figure 3. Topologies of signal peptide peptidase (SPP, left) and presenilin (PS, right)
 Note the inverted orientations of their respective YD and GxGD catalytic motifs, a property that likely accounts for the difference in each enzyme's preference for substrate orientation. This figure has some similarity to a figure presented previously [33].

Protein	10	20	30	Sheddase(s)	Sheddase Regulation	Reference
Alcadin α	HPFAVVPSTATVVI	VVCVSFLVFMILGV	FLVFMILGV	ND	ND	[101]
Alcadin γ	QHS--SVVPSIATVVI	IISVCM	LVFVVMAMGV	ND	ND	[101]
APLP1	AGTGVSREAVSGLL	MGAGG	SSLIVLSMLL	B1	N-glycosylation	[102, 103]
APLP2	REDTFLSSSALIGLLV	IAVAIA	TVIVISLVM	B1, A10, A17	ND	[98, 102-104]
ApoER2	-----MGSTVTA	AVIGIIVP	IVVIALLCMS	ND	apoE, reelin, α2-macroglobulin	[105, 106]
APP	AEDVGSNKGAI	IGLMVGGVV	IATVIVITLVM	X _{39/39} -CO ₂ H	F-spondin	[107-109]
CD43	RNP-DENSRGMLP	VAVLVALLAV	IVLVALL	ND	ND	[110]
CD44	PIR-TPQIPEW	LILASLLA	LALILAVCIAV	ND	hyaluronan, monoclonal	[111-117]
					N-glycosylation	
					ionomycin, mechanical scraping	
					disulfide bonds	
CSF1R	AHT-HPPDEF	LFTPVVV	ACMSIMALL	A17	lipopolysaccharide, IFNγ	[118-120]
CXCL16	PTA---RTS	ATVPVLC	LLAIIFILTA	A10	ND	[121-123]
CX3CL1	-----AQA	ATRRQAV	GLLAFGLFCL	A10, A17	ND	[122-125]
DCC	VTP-QKNSN	LVIIVTV	GVITVLVVIV	ND	ND	[126]
Delta1	SQG---GFPF	WVAVCAG	VVLVLLLLG	A9, A10, A12, A17	Notch	[127-131]
E-cadherin	VEA-GLQIP	AAILGIL	GLALLLILLL	A10	ionomycin, mechanical scraping	[132-134]
EphrinB1	FFN---SKVAL	FAAGAGC	VIFLLIIIFL	ND	ND	[135]
EphrinB2	-----GSE	VALFAG	IASGCI	ND	EphB2	[136]
EphB2	SIK---EKLP	LLIVGSSA	AGLVFLIA	A10	EphrinB2	[137]
					ionomycin, NMDA agonist	
ErbB4	LPQ---HARTP	LIAAGVIG	GLFILVIVGL	A17	heregulin/NGR1	[138-142]
GHR	EACEEDIQF	PWFLII	IFGIFGV	A17	dimerization inhibits cleavage	[143-145]
HLA-A2	SSQ---PTVP	IVGIIAG	LVLF	A10	ND	[146]
IGF1R	TGY---ENFI	HLIALP	VAVLLIV	ND	ND	[147]
IFNαR2	SES---AES	AKIGGI	ITVFLIAL	ND	IFNγ-N-α2, IFNγ-N-β	[148]
IL1R2	KEA---SSTF	SWGIVL	APLSLA	A17, A8	ND	[123, 149]
IR	DVP---SNA	KIATIG	PLVFLF	ND	ND	[150]
Ire1a	-----PVD	SMLKDM	ATILST	ND	ND	[151]
Jagged2	VTG-GSST	GLLV	PVLCGAF	A17	Notch	[130, 131]
L1	PPA-GFATE	GWFIF	GVSAI	A10, A17	NMDA agonist	[152]
LRP	VFS-QQQP	GHIASI	LPLLL	B1, M	O-glycosylation	[106, 153-155]
LRP1B	DHI---STR	SIATIV	PLVLL	ND	ND	[156]
LRP2	KGI---SPGT	TAAYALL	TILLIV	ND	Vitamin-D binding protein	[157]
LRP6	TEEPAPQATN	-----TV	GSVIGV	ND	Wnt3a	[158]
N-cadherin	-GA-GLGT	GATIA	ILLCI	A10	ionomycin, NMDA agonist	[159, 160]
Nectin1α	RAG---PVP	TAIGV	AGSILL	ND	ND	[161]
Notch1	VEP-PPPAQ	LHFMY	VAAAFV	A10, A17	Delta, Jagged	[162-165]
Notch2	LES-PRNAQ	LLYLLA	VAVVIL	ND	Delta, Jagged	[166, 167]
Notch3	EAP-EQSV-	PLPLLV	AGAVFL	ND	ND	[167]
Notch4	PPANQLP	WPILCS	PVGVLL	ND	ND	[167]
NRADD	EPP-GASS-	NIIPVY	CALLAT	ND	N-glycosylation	[168]
p75-NTR	VTR-GTTD-	NLIPVY	CSILAA	A17	neurotrophins; NGF, BDNF	[169-173]
PKHD1	VTRKEKST	IIAAS	SSVASW	ND	A23187	[174, 175]
Pcdh α4	-----DA	ALVD	VNVYLI	A10	homo- and heteromers	[176]
Pcdh γ-C3	-----QK	NLTFFY	LLSLIL	A10	ionomycin, AMPA agonist	[176, 177]
					homo- and heteromers	
					homophilic association	
PTPα	KQT---DRV	VKLAGI	SAGIL	A10	ND	[178]
PTP-LAR	AQQ-QEPE	KLW-V	TGPVL	A17	A23187	[179-181]
SorCS1b	VDLTPTHSG	-----S	AMLML	A17	ND	[182, 183]
SorLA	-----AAR	SDTVA	AVVPI	A17	head-activator	[182-185]
Sortilin	EKQNSKSN	SVPIILA	IVGLML	A17	ND	[182, 183]
Syndecan3	KSI-LERKE	YLVAIV	GGVVG	ND	ND	[186]
Tyrosinase	-----EQ	ASRIWS	LLGAMV	ND	ND	[187]
TYRP1	-SR-EFS	VPETIA	IAIVG	ND	ND	[187]
TYRP2	ETP-----	GWPTT	LLVVMG	ND	ND	[187]
VEGF-R1	TSD---KSN	LELITL	CTCVA	ND	VEGF	[188]
VGSC β2	PER-DSTV	AVIVG	ASVGG	B1	ND	[189, 190]
VLDR	SVPPKGTSA	-----A	WAAILP	ND	apoE, reelin, α2-macroglobulin	[105]

Figure 4. Sequences and properties of γ-secretase substrates

The sequences of 55 known type I membrane protein substrates are presented. Only the first 8 residues of extracellular domain (ECD; unless actual length is shorter) and the first 8 residues of intracellular domain (ICD) are given. The blue region of the multiple sequence alignment (MSA) corresponds to hydrophobic transmembrane residues; the column of arginine and lysine residues highlighted in red are part of stop-transfer signals; the orange-shaded glycine residues are parts of GxxxG motifs (which may be dimerization-prone). γ-Secretase cleavage sites, where known, are immediately to the left of residues displayed in red font. Appropriate references for PS-mediated proteolysis and ectodomain shedding are provided. The colored boxes in the column entitled “Sheddase Regulation” correspond to the known regulatory modes

for prior ectodomain shedding of a particular γ -secretase substrate. Blue boxes indicate that ligand binding controls cleavage, with the cell entries containing the names of the responsible ligand(s). Yellow boxes indicate that differential glycosylation influences ectodomain cleavage. Green boxes indicate that calcium influx promotes ectodomain cleavage: increases in cellular calcium concentrations, either by introduction of an ionophore, mechanical scraping of cells, or use of an NDMA or AMPA receptor agonist, likely directly up-regulate metalloprotease activity. Red boxes indicate that substrate oligomerization affects cleavage. These various regulatory modes are not mutually exclusive and for cases in which multiple modes affect the cleavage of a substrate, the individual contribution of each stimulus has generally not been evaluated. **Abbreviations:** A10=ADAM10/kuzbanian; A17=ADAM17/TACE; B1=BACE1; M=MT1-MMP. The multiple sequence alignment was performed using the bcl_align program (Jens Meiler, unpublished) and used data from various protein structure prediction algorithms. The chromatic visualization was done using Jalview.

Figure 5. Model for γ -secretase substrate recognition and cleavage

A 1:1:1:1 PS:Nct:Aph-1:Pen-2 substrate stoichiometry is depicted in the figure, though the precise stoichiometry is presently unknown. (A) Following ectodomain shedding, the truncated extracellular amino terminus of the substrate (white) makes electrostatic contact with E333 of the nicastrin ectodomain. This interaction positions the substrate at the initial substrate binding site of the complex, located at the interface between the two fragments of the PS heterodimer. (B) The substrate then either physically translocates or kinks (shown) in such a way that the scissile bond is positioned within the catalytic site formed by the transmembrane aspartate residues of PS helices 6 and 7. This model reflects aspects of figures from [62], [207], and [51].

Figure 6. Regulating access of APP to γ -secretase by subcellular trafficking

APP (yellow cylinder) undergoes complex maturation and trafficking throughout the endosomal system, and may be cleaved by secretases in a number of subcellular compartments. The majority of amyloidogenic (BACE) processing appears to occur after internalization of cell-surface APP, possibly in conjunction with LRP (red cylinder) and the adaptor protein, Fe65 (gray cruciform). Myriad proteins have been reported to bind to and modulate the trafficking and processing of APP. Many of these interactions may be mediated by cytosolic adaptor proteins (denoted by the question mark signs). Much of the information presented in this figure must be subjected to additional experimental scrutiny. This figure also does not include the additional level of trafficking that occurs between raft and non-raft fractions of the membrane, nor does it display BACE or γ -secretase trafficking. The activity of these two proteases has been demonstrated to occur at the cell surface and in various compartments of the endosomal system, with the latter thought to represent the principal site of activity.

Figure 7.

Model for processivity of γ -secretase proteolysis. An initial ectodomain shedding event allows substrate recognition by γ -secretase, which then executes successive juxtamembranous and intramembranous cleavage events. γ -Secretase cleavage often yields a transcriptionally-active intracellular domain which can translocate to the nucleus to regulate gene expression.

Helical Propensity of γ -secretase Substrate Relative to Cleavage Site

Figure 8. Helical propensities relative to site of cleavage for γ -secretase substrates

Using a combination of methods — *psipred* configured with two different neural networks and *jufo* [316-318] — we compared residues surrounding the cleavage site for 23 γ -secretase cleavage sites. These methods perform a three-state prediction, assigning a value to each amino acid indicating the probability that it exists in a random coil state, an α -helix, or a β -sheet. The results from the three methods were averaged and graphed as a function of residue number relative to the site of cleavage (position 0 in figure).